Oxygen enhancing membrane systems for implantable devices
First Claim
1. An electrochemical glucose sensor for determining a presence or a concentration of glucose in a fluid, the sensor comprising:
- a multilayer membrane system comprising a cell impermeable domain that is substantially impermeable to cells, a resistance domain configured to restrict a flow of the glucose therethrough, and an enzyme domain comprising an enzyme that reacts with the glucose in the fluid as it passes though the enzyme domain; and
a working electrode comprising a conductive material, wherein the working electrode is configured to measure a product of a reaction of the enzyme with the glucose,wherein the enzyme domain, the resistance domain, and the cell impermeable domain each comprise a polymer material with a higher oxygen solubility than an oxyhydrocarbon polymer and wherein each of the enzyme domain, the resistance domain, and the cell impermeable domain is configured to be permeable to the glucose.
2 Assignments
0 Petitions

Accused Products

Abstract
The present invention relates generally to systems and methods for increasing oxygen availability to implantable devices. The preferred embodiments provide a membrane system configured to provide protection of the device from the biological environment and/or a catalyst for enabling an enzymatic reaction, wherein the membrane system includes a polymer formed from a high oxygen soluble material. The high oxygen soluble polymer material is disposed adjacent to an oxygen-utilizing source on the implantable device so as to dynamically retain high oxygen availability to the oxygen-utilizing source during oxygen deficits. Membrane systems of the preferred embodiments are useful for implantable devices with oxygen-utilizing sources and/or that function in low oxygen environments, such as enzyme-based electrochemical sensors and cell transplantation devices.
647 Citations
Analyte monitoring device and methods of use | ||
Patent #
US 7,885,699 B2
Filed 08/06/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing continuous calibration of implantable analyte sensors | ||
Patent #
US 7,885,698 B2
Filed 02/28/2006
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing data management in data monitoring system | ||
Patent #
US 7,884,729 B2
Filed 08/02/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Integrated transmitter unit and sensor introducer mechanism and methods of use | ||
Patent #
US 7,883,464 B2
Filed 09/30/2005
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 7,869,853 B1
Filed 08/06/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Variable volume, shape memory actuated insulin dispensing pump | ||
Patent #
US 7,922,458 B2
Filed 12/29/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
On-body medical device securement | ||
Patent #
US 7,951,080 B2
Filed 10/30/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring system and method | ||
Patent #
US 7,920,907 B2
Filed 06/07/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring system and methods | ||
Patent #
US 7,928,850 B2
Filed 05/08/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Device and method for determining analyte levels | ||
Patent #
US 7,970,448 B2
Filed 04/19/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and apparatus for providing dynamic multi-stage signal amplification in a medical device | ||
Patent #
US 7,948,369 B2
Filed 08/02/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Variable volume, shape memory actuated insulin dispensing pump | ||
Patent #
US 7,993,109 B2
Filed 12/29/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Variable volume, shape memory actuated insulin dispensing pump | ||
Patent #
US 7,993,108 B2
Filed 04/13/2005
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Smart messages and alerts for an infusion delivery and management system | ||
Patent #
US 7,981,034 B2
Filed 02/28/2006
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Electrochemical analyte sensor | ||
Patent #
US 7,996,054 B2
Filed 02/20/2006
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Device and method for determining analyte levels | ||
Patent #
US 7,974,672 B2
Filed 04/19/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 7,996,158 B2
Filed 05/14/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Techniques to improve polyurethane membranes for implantable glucose sensors | ||
Patent #
US 8,053,018 B2
Filed 01/15/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and system for providing integrated medication infusion and analyte monitoring system | ||
Patent #
US 8,029,460 B2
Filed 12/21/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Variable volume, shape memory actuated insulin dispensing pump | ||
Patent #
US 8,029,245 B2
Filed 12/29/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Glucose measuring device for use in personal area network | ||
Patent #
US 8,066,639 B2
Filed 06/04/2004
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Glucose measuring device integrated into a holster for a personal area network device | ||
Patent #
US 8,029,443 B2
Filed 09/26/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Techniques to improve polyurethane membranes for implantable glucose sensors | ||
Patent #
US 8,050,731 B2
Filed 11/16/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor transmitter unit configuration for a data monitoring and management system | ||
Patent #
US 8,029,441 B2
Filed 02/28/2006
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Variable volume, shape memory actuated insulin dispensing pump | ||
Patent #
US 8,047,812 B2
Filed 12/29/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing integrated medication infusion and analyte monitoring system | ||
Patent #
US 8,029,459 B2
Filed 12/21/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Variable volume, shape memory actuated insulin dispensing pump | ||
Patent #
US 8,047,811 B2
Filed 12/29/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Variable volume, shape memory actuated insulin dispensing pump | ||
Patent #
US 8,029,250 B2
Filed 12/29/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 7,860,544 B2
Filed 03/07/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensors and methods of use | ||
Patent #
US 7,822,455 B2
Filed 07/31/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Device and method for determining analyte levels | ||
Patent #
US 7,792,562 B2
Filed 12/22/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Continuous glucose monitoring system and methods of use | ||
Patent #
US 7,811,231 B2
Filed 12/26/2003
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Dual electrode system for a continuous analyte sensor | ||
Patent #
US 7,761,130 B2
Filed 03/27/2007
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and apparatus for providing peak detection circuitry for data communication systems | ||
Patent #
US 7,679,407 B2
Filed 04/27/2004
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring and management system and methods therefor | ||
Patent #
US 7,801,582 B2
Filed 03/31/2006
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing basal profile modification in analyte monitoring and management systems | ||
Patent #
US 7,766,829 B2
Filed 11/04/2005
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Device and method for determining analyte levels | ||
Patent #
US 7,835,777 B2
Filed 12/22/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and apparatus for providing rechargeable power in data monitoring and management systems | ||
Patent #
US 7,756,561 B2
Filed 09/30/2005
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing data management in data monitoring system | ||
Patent #
US 7,768,408 B2
Filed 05/17/2006
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensors and methods of use | ||
Patent #
US 7,826,879 B2
Filed 02/28/2006
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing dynamic multi-stage signal amplification in a medical device | ||
Patent #
US 7,768,387 B2
Filed 04/14/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing analyte sensor insertion | ||
Patent #
US 7,697,967 B2
Filed 09/28/2006
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 7,768,386 B2
Filed 07/31/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor | ||
Patent #
US 7,828,728 B2
Filed 02/14/2007
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Close proximity communication device and methods | ||
Patent #
US 7,826,382 B2
Filed 05/30/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing temperature sensor module in a data communication system | ||
Patent #
US 20090082693A1
Filed 12/29/2004
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Therasense Incorporated
|
Silicone based membranes for use in implantable glucose sensors | ||
Patent #
US 7,613,491 B2
Filed 04/14/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Enhanced Oxygen Cell Culture Platforms | ||
Patent #
US 20080009027A1
Filed 07/09/2007
|
Current Assignee
University of Miami
|
Original Assignee
University of Miami
|
ANALYTE MONITORING SYSTEM AND METHOD | ||
Patent #
US 20080071158A1
Filed 06/07/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
DIGITAL SIGNAL RECEIVER WITH Q-MONITOR | ||
Patent #
US 20080292026A1
Filed 08/14/2007
|
Current Assignee
Nokia US Holdings. Inc.
|
Original Assignee
Alcatel-Lucent SA
|
Method and apparatus for providing rolling data in communication systems | ||
Patent #
US 8,123,686 B2
Filed 03/01/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Silicone based membranes for use in implantable glucose sensors | ||
Patent #
US 8,064,977 B2
Filed 07/29/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 8,103,471 B2
Filed 05/14/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Signal converting cradle for medical condition monitoring and management system | ||
Patent #
US 8,085,151 B2
Filed 06/26/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method of calibrating of an analyte-measurement device, and associated methods, devices and systems | ||
Patent #
US 8,116,840 B2
Filed 10/30/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing data management in data monitoring system | ||
Patent #
US 8,089,363 B2
Filed 02/07/2011
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
RF tag on test strips, test strip vials and boxes | ||
Patent #
US 8,115,635 B2
Filed 11/24/2009
|
Current Assignee
Therasense Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring and management system and methods therefor | ||
Patent #
US 8,086,292 B2
Filed 10/27/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing rechargeable power in data monitoring and management systems | ||
Patent #
US 8,112,138 B2
Filed 09/26/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing leak detection in data monitoring and management systems | ||
Patent #
US 8,112,240 B2
Filed 04/29/2005
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Device and method for automatic data acquisition and/or detection | ||
Patent #
US 8,121,857 B2
Filed 02/14/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors | ||
Patent #
US 8,135,548 B2
Filed 10/26/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated, University of Virginia Patent Foundation
|
Method and apparatus for providing dynamic multi-stage amplification in a medical device | ||
Patent #
US 8,149,103 B2
Filed 05/23/2011
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring system and methods | ||
Patent #
US 8,149,117 B2
Filed 08/29/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in medical communication system | ||
Patent #
US 8,140,142 B2
Filed 04/14/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for determining analyte levels | ||
Patent #
US 8,140,312 B2
Filed 01/31/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring and management device and method to analyze the frequency of user interaction with the device | ||
Patent #
US 8,160,900 B2
Filed 06/26/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,162,829 B2
Filed 03/30/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,175,673 B2
Filed 11/09/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,177,716 B2
Filed 12/21/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for detecting false hypoglycemic conditions | ||
Patent #
US 8,185,181 B2
Filed 10/29/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Continuous glucose monitoring system and methods of use | ||
Patent #
US 8,187,183 B2
Filed 10/11/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing integrated analyte monitoring and infusion system therapy management | ||
Patent #
US 8,206,296 B2
Filed 08/07/2006
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing analyte monitoring | ||
Patent #
US 8,211,016 B2
Filed 09/26/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method of calibrating an analyte-measurement device, and associated methods, devices and systems | ||
Patent #
US 8,219,175 B2
Filed 06/29/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method of calibrating an analyte-measurement device, and associated methods, devices and systems | ||
Patent #
US 8,219,174 B2
Filed 06/29/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Correlation of alternative site blood and interstitial fluid glucose concentrations to venous glucose concentration | ||
Patent #
US 8,216,138 B1
Filed 10/23/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing analyte monitoring | ||
Patent #
US 8,216,137 B2
Filed 07/20/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Optimizing analyte sensor calibration | ||
Patent #
US 8,219,173 B2
Filed 09/30/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,224,413 B2
Filed 10/10/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and device for providing offset model based calibration for analyte sensor | ||
Patent #
US 8,224,415 B2
Filed 01/29/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
RF tag on test strips, test strip vials and boxes | ||
Patent #
US 8,223,021 B2
Filed 11/24/2009
|
Current Assignee
Therasense Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,226,558 B2
Filed 09/27/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,226,557 B2
Filed 12/28/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,226,555 B2
Filed 03/18/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring devices and methods therefor | ||
Patent #
US 8,226,891 B2
Filed 03/31/2006
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,231,532 B2
Filed 04/30/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 8,239,166 B2
Filed 05/14/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,235,896 B2
Filed 12/21/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for sterilizing an analyte sensor | ||
Patent #
US 8,252,229 B2
Filed 04/10/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Oxygen enhancing membrane systems for implantable devices | ||
Patent #
US 8,255,032 B2
Filed 01/15/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Oxygen enhancing membrane systems for implantable devices | ||
Patent #
US 8,255,030 B2
Filed 04/25/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,255,031 B2
Filed 03/17/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Oxygen enhancing membrane systems for implantable devices | ||
Patent #
US 8,255,033 B2
Filed 04/25/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,260,392 B2
Filed 06/09/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 8,260,558 B2
Filed 05/14/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,265,726 B2
Filed 11/09/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Apparatus for providing power management in data communication systems | ||
Patent #
US 8,273,295 B2
Filed 11/24/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,273,022 B2
Filed 02/13/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,275,439 B2
Filed 11/09/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Implantable analyte sensor | ||
Patent #
US 8,277,713 B2
Filed 05/03/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,287,454 B2
Filed 09/27/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,306,598 B2
Filed 11/09/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing an integrated analyte sensor insertion device and data processing unit | ||
Patent #
US 8,333,714 B2
Filed 09/10/2006
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Fluid delivery device with autocalibration | ||
Patent #
US 8,343,093 B2
Filed 05/28/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing integrated medication infusion and analyte monitoring system | ||
Patent #
US 8,343,092 B2
Filed 11/24/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing a fault tolerant display unit in an electronic device | ||
Patent #
US 8,344,966 B2
Filed 01/31/2006
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,346,336 B2
Filed 03/18/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,346,337 B2
Filed 06/30/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor calibration management | ||
Patent #
US 8,346,335 B2
Filed 01/30/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,353,829 B2
Filed 12/21/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,357,091 B2
Filed 12/21/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
RF tag on test strips, test strip vials and boxes | ||
Patent #
US 8,358,210 B2
Filed 11/24/2009
|
Current Assignee
Therasense Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring system and methods | ||
Patent #
US 8,362,904 B2
Filed 04/18/2011
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise | ||
Patent #
US 8,364,229 B2
Filed 05/18/2007
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,366,614 B2
Filed 03/30/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing data communication in continuous glucose monitoring and management system | ||
Patent #
US 8,368,556 B2
Filed 04/29/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,372,005 B2
Filed 12/21/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor with lag compensation | ||
Patent #
US 8,374,668 B1
Filed 10/23/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing calibration of an analyte sensor in an analyte monitoring system | ||
Patent #
US 8,376,945 B2
Filed 11/23/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Closed loop control system with safety parameters and methods | ||
Patent #
US 8,377,031 B2
Filed 08/31/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,380,273 B2
Filed 04/11/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
RF tag on test strips, test strip vials and boxes | ||
Patent #
US 8,390,455 B2
Filed 11/24/2009
|
Current Assignee
Therasense Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,391,945 B2
Filed 03/17/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,409,131 B2
Filed 03/07/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Assessing measures of glycemic variability | ||
Patent #
US 8,409,093 B2
Filed 10/23/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Device and method for automatic data acquisition and/or detection | ||
Patent #
US 8,417,545 B2
Filed 02/17/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing dynamic multi-stage amplification in a medical device | ||
Patent #
US 8,427,298 B2
Filed 04/02/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for transferring analyte test data | ||
Patent #
US 8,437,966 B2
Filed 11/20/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 8,444,560 B2
Filed 05/14/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring system and methods | ||
Patent #
US 8,456,301 B2
Filed 05/08/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Glucose measuring module and insulin pump combination | ||
Patent #
US 8,460,243 B2
Filed 06/10/2003
|
Current Assignee
Smiths Medical ASD Inc.
|
Original Assignee
Abbott Diabetes Care Incorporated, Deltek Inc.
|
Analyte monitoring system and methods | ||
Patent #
US 8,461,985 B2
Filed 05/08/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Electrochemical analyte sensor | ||
Patent #
US 8,463,351 B2
Filed 08/06/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,465,425 B2
Filed 06/30/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Closed loop blood glucose control algorithm analysis | ||
Patent #
US 8,467,972 B2
Filed 04/28/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing data management in data monitoring system | ||
Patent #
US 8,471,714 B2
Filed 12/30/2011
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,473,021 B2
Filed 07/31/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor with time lag compensation | ||
Patent #
US 8,473,022 B2
Filed 01/30/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing analyte monitoring system calibration accuracy | ||
Patent #
US 8,478,557 B2
Filed 07/30/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,480,580 B2
Filed 04/19/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing real time analyte sensor calibration with retrospective backfill | ||
Patent #
US 8,483,967 B2
Filed 04/28/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for determining analyte levels | ||
Patent #
US 8,484,005 B2
Filed 03/19/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for transferring analyte test data | ||
Patent #
US 8,483,974 B2
Filed 11/20/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring system having an alert | ||
Patent #
US 8,497,777 B2
Filed 04/15/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Signal converting cradle for medical condition monitoring and management system | ||
Patent #
US 8,502,682 B2
Filed 12/23/2011
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing continuous calibration of implantable analyte sensors | ||
Patent #
US 8,506,482 B2
Filed 02/07/2011
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Close proximity communication device and methods | ||
Patent #
US 8,509,107 B2
Filed 11/01/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Sensor head for use with implantable devices | ||
Patent #
US 8,509,871 B2
Filed 10/28/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Integrated introducer and transmitter assembly and methods of use | ||
Patent #
US 8,512,243 B2
Filed 09/30/2005
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing peak detection circuitry for data communication systems | ||
Patent #
US 8,512,246 B2
Filed 03/15/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Glucose measuring device for use in personal area network | ||
Patent #
US 8,512,239 B2
Filed 04/20/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Integrated analyte sensor and infusion device and methods therefor | ||
Patent #
US 8,512,244 B2
Filed 09/26/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for dynamically updating calibration parameters for an analyte sensor | ||
Patent #
US 8,515,517 B2
Filed 09/30/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Displays for a medical device | ||
Patent #
US 8,514,086 B2
Filed 08/30/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Device and method for determining analyte levels | ||
Patent #
US 8,527,025 B1
Filed 11/22/1999
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and device for providing offset model based calibration for analyte sensor | ||
Patent #
US 8,532,935 B2
Filed 07/16/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Glucose measurement device and methods using RFID | ||
Patent #
US 8,542,122 B2
Filed 01/17/2013
|
Current Assignee
Therasense Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Silicone based membranes for use in implantable glucose sensors | ||
Patent #
US 8,543,184 B2
Filed 10/20/2011
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring and management system and methods therefor | ||
Patent #
US 8,543,183 B2
Filed 12/23/2011
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Medical device insertion | ||
Patent #
US 8,545,403 B2
Filed 12/28/2006
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Enhanced oxygen cell culture platforms | ||
Patent #
US 8,551,770 B2
Filed 07/09/2007
|
Current Assignee
University of Miami
|
Original Assignee
University of Miami
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 8,560,038 B2
Filed 05/14/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Particle-containing membrane and particulate electrode for analyte sensors | ||
Patent #
US 8,560,039 B2
Filed 09/17/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and system for transferring analyte test data | ||
Patent #
US 8,560,250 B2
Filed 08/18/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Laboratories Incorporated
|
Computerized determination of insulin pump therapy parameters using real time and retrospective data processing | ||
Patent #
US 8,560,082 B2
Filed 01/30/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for mounting a data transmission device in a communication system | ||
Patent #
US 8,571,624 B2
Filed 12/29/2004
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 8,571,808 B2
Filed 01/23/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Infusion devices and methods | ||
Patent #
US 8,579,853 B2
Filed 10/31/2006
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Polymer membranes for continuous analyte sensors | ||
Patent #
US 8,583,204 B2
Filed 03/05/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor calibration management | ||
Patent #
US 8,583,205 B2
Filed 04/16/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing basal profile modification in analyte monitoring and management systems | ||
Patent #
US 8,585,591 B2
Filed 07/10/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Subcutaneous glucose electrode | ||
Patent #
US 8,588,881 B2
Filed 03/02/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing glycemic control | ||
Patent #
US 8,591,410 B2
Filed 06/01/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring system and methods | ||
Patent #
US 8,593,287 B2
Filed 07/20/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for powering an electronic device | ||
Patent #
US 8,593,109 B2
Filed 11/03/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Health management devices and methods | ||
Patent #
US 8,597,188 B2
Filed 06/20/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,597,189 B2
Filed 03/03/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring devices and methods therefor | ||
Patent #
US 8,597,575 B2
Filed 07/23/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 8,600,681 B2
Filed 05/14/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor introducer and methods of use | ||
Patent #
US 8,602,991 B2
Filed 06/07/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,612,159 B2
Filed 02/16/2004
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 8,612,163 B2
Filed 08/30/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Insertion devices and methods | ||
Patent #
US 8,613,703 B2
Filed 05/29/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte meter with a moveable head and methods of using the same | ||
Patent #
US 8,613,892 B2
Filed 06/30/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Health monitor | ||
Patent #
US 8,617,069 B2
Filed 06/20/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,617,071 B2
Filed 06/21/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Continuous glucose monitoring system and methods of use | ||
Patent #
US 8,622,903 B2
Filed 05/25/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,622,906 B2
Filed 12/21/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Variable rate closed loop control and methods | ||
Patent #
US 8,622,988 B2
Filed 08/31/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for evaluating analyte sensor response characteristics | ||
Patent #
US 8,635,046 B2
Filed 06/22/2011
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data communication in data monitoring and management systems | ||
Patent #
US 8,638,220 B2
Filed 05/23/2011
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,641,619 B2
Filed 12/21/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and structure for securing a monitoring device element | ||
Patent #
US 8,641,618 B2
Filed 06/26/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Glucose measuring device for use in personal area network | ||
Patent #
US 8,647,269 B2
Filed 04/20/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,649,841 B2
Filed 04/03/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,652,043 B2
Filed 07/20/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing data management in data monitoring system | ||
Patent #
US 8,653,977 B2
Filed 06/21/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,660,627 B2
Filed 03/17/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and device for determining elapsed sensor life | ||
Patent #
US 8,665,091 B2
Filed 06/30/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,666,469 B2
Filed 11/16/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,668,645 B2
Filed 01/03/2003
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,670,815 B2
Filed 04/30/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,672,844 B2
Filed 02/27/2004
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and device for early signal attenuation detection using blood glucose measurements | ||
Patent #
US 8,676,513 B2
Filed 06/21/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Device and method for determining analyte levels | ||
Patent #
US 8,676,288 B2
Filed 06/22/2011
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Device and method for automatic data acquisition and/or detection | ||
Patent #
US 8,676,601 B2
Filed 04/08/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 8,682,615 B2
Filed 08/04/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Polymer membranes for continuous analyte sensors | ||
Patent #
US 8,682,408 B2
Filed 03/05/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and system for transferring analyte test data | ||
Patent #
US 8,682,598 B2
Filed 08/27/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Laboratories Incorporated
|
Method of calibrating an analyte-measurement device, and associated methods, devices and systems | ||
Patent #
US 8,684,930 B2
Filed 06/29/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,688,188 B2
Filed 06/30/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
ENHANCED OXYGEN CELL CULTURE PLATFORMS | ||
Patent #
US 20140099717A1
Filed 10/07/2013
|
Current Assignee
University of Miami
|
Original Assignee
University of Miami
|
Method and apparatus for providing dynamic multi-stage signal amplification in a medical device | ||
Patent #
US 8,698,615 B2
Filed 04/22/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Electrochemical analyte sensor | ||
Patent #
US 8,706,180 B2
Filed 06/10/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Mitigating single point failure of devices in an analyte monitoring system and methods thereof | ||
Patent #
US 8,710,993 B2
Filed 11/21/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor calibration management | ||
Patent #
US 8,718,739 B2
Filed 12/28/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing analyte monitoring system calibration accuracy | ||
Patent #
US 8,718,965 B2
Filed 06/24/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors | ||
Patent #
US 8,718,958 B2
Filed 03/12/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated, University of Virginia Patent Foundation
|
Method and system for providing integrated analyte monitoring and infusion system therapy management | ||
Patent #
US 8,727,982 B2
Filed 06/25/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring system having an alert | ||
Patent #
US 8,730,058 B2
Filed 07/29/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,734,348 B2
Filed 03/17/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
On-body medical device securement | ||
Patent #
US 8,734,344 B2
Filed 05/29/2011
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Closed loop control with improved alarm functions | ||
Patent #
US 8,734,422 B2
Filed 08/31/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,734,346 B2
Filed 04/30/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Close proximity communication device and methods | ||
Patent #
US 8,737,259 B2
Filed 08/05/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,738,109 B2
Filed 03/03/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Subcutaneous glucose electrode | ||
Patent #
US 8,741,590 B2
Filed 04/03/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Optimizing analyte sensor calibration | ||
Patent #
US 8,744,547 B2
Filed 07/09/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Cellulosic-based resistance domain for an analyte sensor | ||
Patent #
US 8,744,546 B2
Filed 04/28/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,744,545 B2
Filed 03/03/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Medical device inserters and processes of inserting and using medical devices | ||
Patent #
US 8,764,657 B2
Filed 03/30/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing data communication in continuous glucose monitoring and management system | ||
Patent #
US 8,771,183 B2
Filed 02/16/2005
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,774,887 B2
Filed 03/24/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Robust closed loop control and methods | ||
Patent #
US 8,795,252 B2
Filed 10/16/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Real time management of data relating to physiological control of glucose levels | ||
Patent #
US 8,798,934 B2
Filed 07/23/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for sterilizing an analyte sensor | ||
Patent #
US 8,802,006 B2
Filed 08/27/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Displays for a medical device | ||
Patent #
US 8,816,862 B2
Filed 08/19/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing analyte sensor calibration | ||
Patent #
US 8,834,366 B2
Filed 07/31/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,840,553 B2
Filed 02/26/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing analyte sensor insertion | ||
Patent #
US 8,852,101 B2
Filed 09/30/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing an integrated analyte sensor insertion device and data processing unit | ||
Patent #
US 8,862,198 B2
Filed 12/17/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Techniques to improve polyurethane membranes for implantable glucose sensors | ||
Patent #
US 8,865,249 B2
Filed 09/28/2012
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Closed loop control system interface and methods | ||
Patent #
US 8,876,755 B2
Filed 07/14/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,880,137 B2
Filed 04/18/2003
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Device for channeling fluid and methods of use | ||
Patent #
US 8,880,138 B2
Filed 09/30/2005
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor | ||
Patent #
US 8,900,431 B2
Filed 08/25/2009
|
Current Assignee
Edwards Lifesciences Corporation
|
Original Assignee
Edwards Lifesciences Corporation
|
Oxygen enhancing membrane systems for implantable devices | ||
Patent #
US 8,909,314 B2
Filed 07/20/2011
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Apparatus for providing power management in data communication systems | ||
Patent #
US 8,906,307 B2
Filed 08/18/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,915,850 B2
Filed 03/28/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,920,319 B2
Filed 12/28/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing glycemic control | ||
Patent #
US 8,924,159 B2
Filed 06/01/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Dual electrode system for a continuous analyte sensor | ||
Patent #
US 8,929,968 B2
Filed 07/19/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Multi-function analyte test device and methods therefor | ||
Patent #
US 8,930,203 B2
Filed 02/03/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for powering an electronic device | ||
Patent #
US 8,933,664 B2
Filed 11/25/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing data management in integrated analyte monitoring and infusion system | ||
Patent #
US 8,932,216 B2
Filed 08/07/2006
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing dynamic multi-stage signal amplification in a medical device | ||
Patent #
US 8,937,540 B2
Filed 02/24/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Polymer membranes for continuous analyte sensors | ||
Patent #
US 8,954,128 B2
Filed 10/18/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,974,386 B2
Filed 11/01/2005
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor sensitivity attenuation mitigation | ||
Patent #
US 8,986,208 B2
Filed 09/30/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring system and methods for managing power and noise | ||
Patent #
US 8,993,331 B2
Filed 08/31/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring system and methods | ||
Patent #
US 9,000,929 B2
Filed 11/22/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in medical communication system | ||
Patent #
US 9,008,743 B2
Filed 04/14/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,011,332 B2
Filed 10/30/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,011,331 B2
Filed 12/29/2004
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,014,773 B2
Filed 03/07/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensors and methods of use | ||
Patent #
US 9,031,630 B2
Filed 11/01/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring system and methods | ||
Patent #
US 9,035,767 B2
Filed 05/30/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring devices and methods therefor | ||
Patent #
US 9,039,975 B2
Filed 12/02/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,042,953 B2
Filed 03/02/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for detecting false hypoglycemic conditions | ||
Patent #
US 9,050,041 B2
Filed 05/21/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Infusion devices and methods | ||
Patent #
US 9,064,107 B2
Filed 09/30/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 9,060,719 B2
Filed 12/13/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,066,695 B2
Filed 04/12/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,066,697 B2
Filed 10/27/2011
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and device for early signal attenuation detection using blood glucose measurements | ||
Patent #
US 9,066,709 B2
Filed 03/17/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Electronic devices having integrated reset systems and methods thereof | ||
Patent #
US 9,069,536 B2
Filed 10/30/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,066,694 B2
Filed 04/03/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,072,477 B2
Filed 06/21/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,078,607 B2
Filed 06/17/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing data communication in continuous glucose monitoring and management system | ||
Patent #
US 9,088,452 B2
Filed 01/31/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing rolling data in communication systems | ||
Patent #
US 9,095,290 B2
Filed 02/27/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing power management in data communication systems | ||
Patent #
US 9,109,926 B2
Filed 12/08/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing analyte monitoring | ||
Patent #
US 9,113,828 B2
Filed 07/09/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Integrated analyte sensor and infusion device and methods therefor | ||
Patent #
US 9,119,582 B2
Filed 06/30/2006
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 9,125,548 B2
Filed 05/14/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Polymer membranes for continuous analyte sensors | ||
Patent #
US 9,173,607 B2
Filed 01/30/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Enhanced oxygen cell culture platforms | ||
Patent #
US 9,175,254 B2
Filed 10/07/2013
|
Current Assignee
University of Miami
|
Original Assignee
University of Miami
|
Analyte monitoring system and methods | ||
Patent #
US 9,177,456 B2
Filed 06/10/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring system having an alert | ||
Patent #
US 9,178,752 B2
Filed 04/25/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Polymer membranes for continuous analyte sensors | ||
Patent #
US 9,173,606 B2
Filed 01/30/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Techniques to improve polyurethane membranes for implantable glucose sensors | ||
Patent #
US 9,179,869 B2
Filed 09/10/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Close proximity communication device and methods | ||
Patent #
US 9,184,875 B2
Filed 04/25/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Medical device inserters and processes of inserting and using medical devices | ||
Patent #
US 9,186,098 B2
Filed 03/24/2011
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Displays for a medical device | ||
Patent #
US 9,186,113 B2
Filed 08/11/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in medical communication system | ||
Patent #
US 9,204,827 B2
Filed 04/14/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Medical device inserters and processes of inserting and using medical devices | ||
Patent #
US 9,215,992 B2
Filed 03/24/2011
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Displays for a medical device | ||
Patent #
US 9,226,714 B2
Filed 01/08/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Error detection in critical repeating data in a wireless sensor system | ||
Patent #
US 9,226,701 B2
Filed 04/28/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Flexible patch for fluid delivery and monitoring body analytes | ||
Patent #
US 9,259,175 B2
Filed 10/23/2006
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Medical device inserters and processes of inserting and using medical devices | ||
Patent #
US 9,265,453 B2
Filed 03/24/2011
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Mitigating single point failure of devices in an analyte monitoring system and methods thereof | ||
Patent #
US 9,289,179 B2
Filed 04/11/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing real time analyte sensor calibration with retrospective backfill | ||
Patent #
US 9,310,230 B2
Filed 06/24/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Compatibility mechanisms for devices in a continuous analyte monitoring system and methods thereof | ||
Patent #
US 9,317,656 B2
Filed 11/21/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring system and methods | ||
Patent #
US 9,314,198 B2
Filed 04/03/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte signal processing device and methods | ||
Patent #
US 9,314,195 B2
Filed 08/31/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing notification function in analyte monitoring systems | ||
Patent #
US 9,320,461 B2
Filed 09/29/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor calibration management | ||
Patent #
US 9,320,462 B2
Filed 05/05/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing basal profile modification in analyte monitoring and management systems | ||
Patent #
US 9,323,898 B2
Filed 11/15/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor with time lag compensation | ||
Patent #
US 9,320,468 B2
Filed 06/21/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
On-body medical device securement | ||
Patent #
US 9,326,727 B2
Filed 05/15/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Systems, devices and methods for managing glucose levels | ||
Patent #
US 9,326,709 B2
Filed 03/09/2011
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,326,716 B2
Filed 12/05/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Sensor head for use with implantable devices | ||
Patent #
US 9,328,371 B2
Filed 07/16/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,326,714 B2
Filed 06/29/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Alarm characterization for analyte monitoring devices and systems | ||
Patent #
US 9,326,707 B2
Filed 11/10/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing data management in data monitoring system | ||
Patent #
US 9,332,944 B2
Filed 01/31/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor with lag compensation | ||
Patent #
US 9,332,934 B2
Filed 02/08/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing analyte sensor insertion | ||
Patent #
US 9,332,933 B2
Filed 09/29/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Device and method for determining analyte levels | ||
Patent #
US 9,339,223 B2
Filed 12/30/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Particle-containing membrane and particulate electrode for analyte sensors | ||
Patent #
US 9,339,222 B2
Filed 05/31/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring system and methods of use | ||
Patent #
US 9,339,217 B2
Filed 11/21/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Interconnect for on-body analyte monitoring device | ||
Patent #
US 9,351,669 B2
Filed 09/30/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for dynamically updating calibration parameters for an analyte sensor | ||
Patent #
US 9,357,959 B2
Filed 08/19/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor transmitter unit configuration for a data monitoring and management system | ||
Patent #
US 9,364,149 B2
Filed 10/03/2011
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for powering an electronic device | ||
Patent #
US 9,380,971 B2
Filed 12/05/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Closed loop control and signal attenuation detection | ||
Patent #
US 9,392,969 B2
Filed 08/31/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing analyte sensor calibration | ||
Patent #
US 9,398,872 B2
Filed 08/28/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing analyte sensor and data processing device | ||
Patent #
US 9,398,882 B2
Filed 09/10/2006
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing dynamic multi-stage signal amplification in a medical device | ||
Patent #
US 9,402,584 B2
Filed 01/14/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor and apparatus for insertion of the sensor | ||
Patent #
US 9,402,544 B2
Filed 02/01/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor devices, connections, and methods | ||
Patent #
US 9,402,570 B2
Filed 12/11/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing calibration of an analyte sensor in an analyte monitoring system | ||
Patent #
US 9,408,566 B2
Filed 02/13/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Assessing measures of glycemic variability | ||
Patent #
US 9,439,586 B2
Filed 03/29/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Device and method for determining analyte levels | ||
Patent #
US 9,439,589 B2
Filed 11/25/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Electronic devices having integrated reset systems and methods thereof | ||
Patent #
US 9,465,420 B2
Filed 06/26/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Multi-rate analyte sensor data collection with sample rate configurable signal processing | ||
Patent #
US 9,474,475 B1
Filed 03/13/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Integrated introducer and transmitter assembly and methods of use | ||
Patent #
US 9,480,421 B2
Filed 08/19/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 9,483,608 B2
Filed 05/20/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,498,159 B2
Filed 10/30/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor retention mechanism and methods of use | ||
Patent #
US 9,521,968 B2
Filed 09/30/2005
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same | ||
Patent #
US 9,532,737 B2
Filed 02/28/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing glycemic control | ||
Patent #
US 9,541,556 B2
Filed 11/25/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Displays for a medical device | ||
Patent #
US 9,549,694 B2
Filed 11/11/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Silicone based membranes for use in implantable glucose sensors | ||
Patent #
US 9,549,693 B2
Filed 07/25/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Polymer membranes for continuous analyte sensors | ||
Patent #
US 9,549,699 B2
Filed 10/17/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and system for determining analyte levels | ||
Patent #
US 9,558,325 B2
Filed 06/24/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Polymer membranes for continuous analyte sensors | ||
Patent #
US 9,566,026 B2
Filed 10/17/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Devices, systems and methods for on-skin or on-body mounting of medical devices | ||
Patent #
US 9,572,534 B2
Filed 06/28/2011
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Robust closed loop control and methods | ||
Patent #
US 9,572,934 B2
Filed 08/01/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Polymer membranes for continuous analyte sensors | ||
Patent #
US 9,572,523 B2
Filed 09/22/2015
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and device for determining elapsed sensor life | ||
Patent #
US 9,574,914 B2
Filed 03/03/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Oxygen enhancing membrane systems for implantable devices | ||
Patent #
US 9,597,027 B2
Filed 10/30/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,610,034 B2
Filed 11/09/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Closed loop control with improved alarm functions | ||
Patent #
US 9,610,046 B2
Filed 04/29/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in medical communication system | ||
Patent #
US 9,615,780 B2
Filed 04/14/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Model based variable risk false glucose threshold alarm prevention mechanism | ||
Patent #
US 9,622,691 B2
Filed 10/30/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring devices and methods therefor | ||
Patent #
US 9,625,413 B2
Filed 05/19/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for dynamically updating calibration parameters for an analyte sensor | ||
Patent #
US 9,629,578 B2
Filed 03/26/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor and apparatus for insertion of the sensor | ||
Patent #
US 9,636,068 B2
Filed 06/24/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Pump system modular components for delivering medication and analyte sensing at seperate insertion sites | ||
Patent #
US 9,636,450 B2
Filed 02/15/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Udo Hoss, Gary A. Stafford
|
Analyte monitoring system and methods | ||
Patent #
US 9,649,057 B2
Filed 05/11/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Optimizing analyte sensor calibration | ||
Patent #
US 9,662,056 B2
Filed 05/22/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing basal profile modification in analyte monitoring and management systems | ||
Patent #
US 9,669,162 B2
Filed 03/16/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Sensitivity calibration of in vivo sensors used to measure analyte concentration | ||
Patent #
US 9,675,290 B2
Filed 10/29/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Medical device inserters and processes of inserting and using medical devices | ||
Patent #
US 9,687,183 B2
Filed 03/30/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing data communication in continuous glucose monitoring and management system | ||
Patent #
US 9,693,688 B2
Filed 07/16/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor devices, connections, and methods | ||
Patent #
US 9,693,713 B2
Filed 06/27/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Polymer membranes for continuous analyte sensors | ||
Patent #
US 9,693,721 B2
Filed 06/17/2015
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and system for providing data management in integrated analyte monitoring and infusion system | ||
Patent #
US 9,697,332 B2
Filed 12/08/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Compatibility mechanisms for devices in a continuous analyte monitoring system and methods thereof | ||
Patent #
US 9,721,063 B2
Filed 03/09/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Glucose measuring device for use in personal area network | ||
Patent #
US 9,730,584 B2
Filed 02/10/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor calibration management | ||
Patent #
US 9,730,623 B2
Filed 02/05/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Alarm characterization for analyte monitoring devices and systems | ||
Patent #
US 9,730,650 B2
Filed 01/15/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 9,737,249 B2
Filed 06/17/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing dynamic multi-stage signal amplification in a medical device | ||
Patent #
US 9,743,866 B2
Filed 07/13/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for powering an electronic device | ||
Patent #
US 9,743,863 B2
Filed 06/01/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Assessing measures of glycemic variability | ||
Patent #
US 9,743,865 B2
Filed 06/25/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Systems and methods for transcutaneously implanting medical devices | ||
Patent #
US 9,743,862 B2
Filed 03/29/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Mitigating single point failure of devices in an analyte monitoring system and methods thereof | ||
Patent #
US 9,743,872 B2
Filed 02/04/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing data management in data monitoring system | ||
Patent #
US 9,750,440 B2
Filed 04/12/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Interconnect for on-body analyte monitoring device | ||
Patent #
US 9,750,444 B2
Filed 04/27/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing notification function in analyte monitoring systems | ||
Patent #
US 9,750,439 B2
Filed 04/08/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise | ||
Patent #
US 9,763,609 B2
Filed 01/02/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor with time lag compensation | ||
Patent #
US 9,770,211 B2
Filed 04/08/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Integrated introducer and transmitter assembly and methods of use | ||
Patent #
US 9,775,563 B2
Filed 09/21/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Smart messages and alerts for an infusion delivery and management system | ||
Patent #
US 9,782,076 B2
Filed 07/18/2011
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Variable speed sensor insertion devices and methods of use | ||
Patent #
US 9,788,771 B2
Filed 10/23/2006
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Continuous analyte measurement systems and systems and methods for implanting them | ||
Patent #
US 9,795,326 B2
Filed 07/22/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing glycemic control | ||
Patent #
US 9,795,328 B2
Filed 01/06/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing analyte sensor insertion | ||
Patent #
US 9,795,331 B2
Filed 04/28/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 9,797,880 B2
Filed 10/11/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Techniques to improve polyurethane membranes for implantable glucose sensors | ||
Patent #
US 9,801,574 B2
Filed 10/05/2015
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and apparatus for providing rolling data in communication systems | ||
Patent #
US 9,801,545 B2
Filed 07/30/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in medical communication system | ||
Patent #
US 9,801,571 B2
Filed 09/16/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Sensitivity calibration of in vivo sensors used to measure analyte concentration | ||
Patent #
US 9,801,577 B2
Filed 06/07/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 9,804,150 B2
Filed 03/24/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor with lag compensation | ||
Patent #
US 9,804,148 B2
Filed 04/29/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Sensor head for use with implantable devices | ||
Patent #
US 9,804,114 B2
Filed 03/02/2016
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and system for providing an integrated analyte sensor insertion device and data processing unit | ||
Patent #
US 9,808,186 B2
Filed 09/26/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Displays for a medical device | ||
Patent #
US 9,814,416 B2
Filed 12/13/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing analyte monitoring | ||
Patent #
US 9,814,428 B2
Filed 08/22/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Close proximity communication device and methods | ||
Patent #
US 9,831,985 B2
Filed 09/29/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing calibration of an analyte sensor in an analyte monitoring system | ||
Patent #
US 9,833,181 B2
Filed 07/13/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for dynamically updating calibration parameters for an analyte sensor | ||
Patent #
US 9,839,383 B2
Filed 04/21/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensors and methods of use | ||
Patent #
US 9,844,329 B2
Filed 05/06/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors | ||
Patent #
US 9,882,660 B2
Filed 04/30/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated, University of Virginia Patent Foundation
|
Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data | ||
Patent #
US 9,907,492 B2
Filed 09/18/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring and management device and method to analyze the frequency of user interaction with the device | ||
Patent #
US 9,913,600 B2
Filed 02/23/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Model based variable risk false glucose threshold alarm prevention mechanism | ||
Patent #
US 9,913,619 B2
Filed 04/13/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing glycemic control | ||
Patent #
US 9,931,075 B2
Filed 11/12/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Device and method for determining analyte levels | ||
Patent #
US 9,931,067 B2
Filed 09/13/2016
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor devices, connections, and methods | ||
Patent #
US 9,931,066 B2
Filed 05/31/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing analyte monitoring and therapy management system accuracy | ||
Patent #
US 9,936,910 B2
Filed 04/25/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Closed loop control with reference measurement and methods thereof | ||
Patent #
US 9,943,644 B2
Filed 08/31/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing data communication in continuous glucose monitoring and management system | ||
Patent #
US 9,949,639 B2
Filed 06/27/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and device for determining elapsed sensor life | ||
Patent #
US 9,949,678 B2
Filed 02/16/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Continuous glucose monitoring system and methods of use | ||
Patent #
US 9,962,091 B2
Filed 01/06/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte signal processing device and methods | ||
Patent #
US 9,968,302 B2
Filed 04/04/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems | ||
Patent #
US 9,968,306 B2
Filed 10/21/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Sensor inserter assembly | ||
Patent #
US 9,980,670 B2
Filed 04/03/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods | ||
Patent #
US 9,980,669 B2
Filed 11/07/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Oxygen enhancing membrane systems for implantable devices | ||
Patent #
US 9,993,186 B2
Filed 02/09/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor and apparatus for insertion of the sensor | ||
Patent #
US 9,993,188 B2
Filed 03/31/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 10,002,233 B2
Filed 05/14/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Infusion devices and methods | ||
Patent #
US 10,007,759 B2
Filed 06/03/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring system having an alert | ||
Patent #
US 10,009,244 B2
Filed 10/30/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Medical device inserters and processes of inserting and using medical devices | ||
Patent #
US 10,010,280 B2
Filed 03/30/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Device and method for automatic data acquisition and/or detection | ||
Patent #
US 10,022,499 B2
Filed 08/18/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Introducer assembly and methods of use | ||
Patent #
US 10,028,680 B2
Filed 03/19/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Particle-containing membrane and particulate electrode for analyte sensors | ||
Patent #
US 10,028,683 B2
Filed 10/07/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Particle-containing membrane and particulate electrode for analyte sensors | ||
Patent #
US 10,028,684 B2
Filed 09/21/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 10,031,002 B2
Filed 12/02/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing data communication in continuous glucose monitoring and management system | ||
Patent #
US 10,039,881 B2
Filed 07/07/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor sensitivity attenuation mitigation | ||
Patent #
US 10,045,739 B2
Filed 03/23/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 10,045,720 B2
Filed 10/15/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Silicone based membranes for use in implantable glucose sensors | ||
Patent #
US 10,052,051 B2
Filed 10/27/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Sensor insertion devices and methods of use | ||
Patent #
US 10,070,810 B2
Filed 10/10/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Sensor fault detection using analyte sensor data pattern comparison | ||
Patent #
US 10,076,285 B2
Filed 03/13/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Systems, devices and methods for managing glucose levels | ||
Patent #
US 10,078,380 B2
Filed 04/07/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring system and methods of use | ||
Patent #
US 10,082,493 B2
Filed 04/29/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and device for providing offset model based calibration for analyte sensor | ||
Patent #
US 10,089,446 B2
Filed 09/03/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Calibration of analyte measurement system | ||
Patent #
US 10,092,229 B2
Filed 06/29/2011
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in medical communication system | ||
Patent #
US 10,111,608 B2
Filed 04/14/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing continuous calibration of implantable analyte sensors | ||
Patent #
US 10,117,614 B2
Filed 09/11/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for detecting false hypoglycemic conditions | ||
Patent #
US 10,117,606 B2
Filed 06/03/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 10,119,956 B2
Filed 10/27/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Displays for a medical device | ||
Patent #
US 10,123,752 B2
Filed 11/10/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Dropout detection in continuous analyte monitoring data during data excursions | ||
Patent #
US 10,132,793 B2
Filed 08/20/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Medical devices and methods | ||
Patent #
US 10,136,816 B2
Filed 08/31/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same | ||
Patent #
US 10,136,845 B2
Filed 03/14/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Mitigating single point failure of devices in an analyte monitoring system and methods thereof | ||
Patent #
US 10,136,847 B2
Filed 08/24/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 10,143,409 B2
Filed 10/27/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Polymer membranes for continuous analyte sensors | ||
Patent #
US 10,143,410 B2
Filed 06/01/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Techniques to improve polyurethane membranes for implantable glucose sensors | ||
Patent #
US 10,154,807 B2
Filed 09/27/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor transmitter unit configuration for a data monitoring and management system | ||
Patent #
US 10,159,433 B2
Filed 04/18/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing data communication in continuous glucose monitoring and management system | ||
Patent #
US 10,172,518 B2
Filed 04/13/2018
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Closed loop control system with safety parameters and methods | ||
Patent #
US 10,173,007 B2
Filed 02/13/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring system and methods | ||
Patent #
US 10,178,954 B2
Filed 05/09/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Sensitivity calibration of in vivo sensors used to measure analyte concentration | ||
Patent #
US 10,188,334 B2
Filed 10/20/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Calibration techniques for a continuous analyte sensor | ||
Patent #
US 10,188,333 B2
Filed 08/17/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Closed loop control and signal attenuation detection | ||
Patent #
US 10,188,794 B2
Filed 06/16/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Integrated transmitter unit and sensor introducer mechanism and methods of use | ||
Patent #
US 10,194,863 B2
Filed 02/07/2011
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing dynamic multi-stage signal amplification in a medical device | ||
Patent #
US 10,194,846 B2
Filed 08/25/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing analyte monitoring | ||
Patent #
US 10,194,868 B2
Filed 11/10/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Accuracy of continuous glucose sensors | ||
Patent #
US 10,194,850 B2
Filed 07/14/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Methods and systems for early signal attenuation detection and processing | ||
Patent #
US 10,194,844 B2
Filed 03/04/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 10,201,301 B2
Filed 04/18/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing integrated analyte monitoring and infusion system therapy management | ||
Patent #
US 10,206,629 B2
Filed 04/28/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing data management in data monitoring system | ||
Patent #
US 10,206,611 B2
Filed 08/23/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Systems, devices, and methods for assembling an applicator and sensor control device | ||
Patent #
US 10,213,139 B2
Filed 05/13/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Integrated analyte sensor and infusion device and methods therefor | ||
Patent #
US 10,220,145 B2
Filed 08/11/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Sensor inserter having introducer | ||
Patent #
US 10,226,207 B2
Filed 09/28/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 10,231,654 B2
Filed 06/23/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Displays for a medical device | ||
Patent #
US RE47,315 E1
Filed 06/30/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 10,261,069 B2
Filed 10/20/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing calibration of an analyte sensor in an analyte monitoring system | ||
Patent #
US 10,278,630 B2
Filed 11/30/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Medical device inserters and processes of inserting and using medical devices | ||
Patent #
US 10,292,632 B2
Filed 10/15/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Cellulosic-based resistance domain for an analyte sensor | ||
Patent #
US 10,300,507 B2
Filed 02/14/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and apparatus for providing analyte sensor insertion | ||
Patent #
US 10,307,091 B2
Filed 10/20/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing glycemic control | ||
Patent #
US 10,327,682 B2
Filed 10/20/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Closed loop control system interface and methods | ||
Patent #
US 10,328,201 B2
Filed 10/30/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for dynamically updating calibration parameters for an analyte sensor | ||
Patent #
US 10,342,469 B2
Filed 12/08/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Integrated introducer and transmitter assembly and methods of use | ||
Patent #
US 10,342,489 B2
Filed 09/25/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Dropout detection in continuous analyte monitoring data during data excursions | ||
Patent #
US 10,345,291 B2
Filed 11/16/2018
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing notification function in analyte monitoring systems | ||
Patent #
US 10,349,874 B2
Filed 08/31/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in medical communication system | ||
Patent #
US 10,349,877 B2
Filed 04/03/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and system for providing an integrated analyte sensor insertion device and data processing unit | ||
Patent #
US 10,362,972 B2
Filed 10/17/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Flexible patch for fluid delivery and monitoring body analytes | ||
Patent #
US 10,363,363 B2
Filed 01/06/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise | ||
Patent #
US 10,376,143 B2
Filed 12/31/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring system and methods for managing power and noise | ||
Patent #
US 10,429,250 B2
Filed 03/26/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Noise rejection methods and apparatus for sparsely sampled analyte sensor data | ||
Patent #
US 10,433,773 B1
Filed 03/13/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Smart messages and alerts for an infusion delivery and management system | ||
Patent #
US 10,448,834 B2
Filed 10/05/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Displays for a medical device | ||
Patent #
US 10,456,091 B2
Filed 11/05/2018
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor calibration management | ||
Patent #
US 10,463,288 B2
Filed 08/11/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 10,463,310 B2
Filed 09/07/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 10,478,108 B2
Filed 02/05/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Medical devices and methods | ||
Patent #
US 10,492,685 B2
Filed 08/31/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Advanced analyte sensor calibration and error detection | ||
Patent #
US 10,555,695 B2
Filed 07/02/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for display device and sensor electronics unit communication | ||
Patent #
US 10,561,349 B2
Filed 03/28/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Particle-containing membrane and particulate electrode for analyte sensors | ||
Patent #
US 10,561,352 B2
Filed 07/03/2018
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Advanced analyte sensor calibration and error detection | ||
Patent #
US 10,561,354 B2
Filed 07/02/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for display device and sensor electronics unit communication | ||
Patent #
US 10,568,552 B2
Filed 03/28/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data for sensor calibration | ||
Patent #
US 10,610,137 B2
Filed 06/28/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data for sensor calibration | ||
Patent #
US 10,610,136 B2
Filed 06/28/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Oxygen enhancing membrane systems for implantable devices | ||
Patent #
US 10,610,140 B2
Filed 05/11/2018
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Advanced analyte sensor calibration and error detection | ||
Patent #
US 10,610,141 B2
Filed 09/27/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data for sensor calibration | ||
Patent #
US 10,610,135 B2
Filed 06/28/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and system for providing data communication in continuous glucose monitoring and management system | ||
Patent #
US 10,617,296 B2
Filed 01/07/2019
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
System and methods for processing analyte sensor data for sensor calibration | ||
Patent #
US 10,617,336 B2
Filed 06/28/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Device and method for automatic data acquisition and/or detection | ||
Patent #
US 10,617,823 B2
Filed 06/27/2018
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Advanced analyte sensor calibration and error detection | ||
Patent #
US 10,624,568 B2
Filed 08/13/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 10,634,662 B2
Filed 11/05/2018
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor on body unit | ||
Patent #
US D882,432 S1
Filed 04/18/2019
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring system and methods | ||
Patent #
US 10,653,317 B2
Filed 01/10/2019
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 10,653,344 B2
Filed 11/19/2018
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Dropout detection in continuous analyte monitoring data during data excursions | ||
Patent #
US 10,656,139 B2
Filed 07/08/2019
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Methods and devices for analyte monitoring calibration | ||
Patent #
US 10,660,554 B2
Filed 03/08/2018
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Compact medical device inserters and related systems and methods | ||
Patent #
US 10,674,944 B2
Filed 05/13/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Advanced analyte sensor calibration and error detection | ||
Patent #
US 10,682,084 B2
Filed 05/07/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Insulin delivery apparatuses capable of bluetooth data transmission | ||
Patent #
US 10,685,749 B2
Filed 12/28/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
System and methods for processing analyte sensor data for sensor calibration | ||
Patent #
US 10,709,364 B2
Filed 11/21/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data for sensor calibration | ||
Patent #
US 10,716,498 B2
Filed 11/21/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Advanced analyte sensor calibration and error detection | ||
Patent #
US 10,722,162 B2
Filed 09/27/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Introducer assembly and methods of use | ||
Patent #
US 10,736,547 B2
Filed 07/09/2018
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
System and methods for processing analyte sensor data for sensor calibration | ||
Patent #
US 10,743,801 B2
Filed 11/21/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Continuous glucose monitoring system and methods of use | ||
Patent #
US 10,750,952 B2
Filed 03/26/2018
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Interconnect for on-body analyte monitoring device | ||
Patent #
US 10,765,351 B2
Filed 08/10/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Medical device inserters and processes of inserting and using medical devices | ||
Patent #
US 10,772,547 B1
Filed 06/19/2020
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Displays for a medical device | ||
Patent #
US 10,772,572 B2
Filed 10/25/2019
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Measurement of glucose in an insulin delivery catheter by minimizing the adverse effects of insulin preservatives | ||
Patent #
US 10,780,222 B2
Filed 05/31/2016
|
Current Assignee
Pacific Diabetes Technologies
|
Original Assignee
Pacific Diabetes Technologies Inc.
|
Analyte sensor and apparatus for insertion of the sensor | ||
Patent #
US 10,786,190 B2
Filed 01/07/2020
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise | ||
Patent #
US 10,791,928 B2
Filed 02/20/2020
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for display device and sensor electronics unit communication | ||
Patent #
US 10,799,157 B2
Filed 08/29/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Method and apparatus for providing data processing and control in a medical communication system | ||
Patent #
US 10,820,841 B2
Filed 08/09/2018
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Methods and systems for early signal attenuation detection and processing | ||
Patent #
US 10,820,842 B2
Filed 06/18/2020
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Continuous analyte measurement systems and systems and methods for implanting them | ||
Patent #
US 10,827,954 B2
Filed 10/20/2017
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Advanced analyte sensor calibration and error detection | ||
Patent #
US 10,835,162 B2
Filed 09/27/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor control unit | ||
Patent #
US D902,408 S1
Filed 03/15/2019
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data | ||
Patent #
US 10,842,420 B2
Filed 03/02/2018
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor device | ||
Patent #
US D903,877 S1
Filed 01/25/2019
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Remote monitoring of analyte measurements | ||
Patent #
US 10,856,736 B2
Filed 03/26/2020
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring and management device and method to analyze the frequency of user interaction with the device | ||
Patent #
US 10,856,785 B2
Filed 03/08/2018
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
System and methods for processing analyte sensor data for sensor calibration | ||
Patent #
US 10,856,787 B2
Filed 07/31/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Remote monitoring of analyte measurements | ||
Patent #
US 10,860,687 B2
Filed 06/23/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Remote monitoring of analyte measurements | ||
Patent #
US 10,869,599 B2
Filed 03/26/2020
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Real time management of data relating to physiological control of glucose levels | ||
Patent #
US 10,872,102 B2
Filed 08/01/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Devices, systems and methods for on-skin or on-body mounting of medical devices | ||
Patent #
US 10,874,338 B2
Filed 06/19/2020
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Multi-rate analyte sensor data collection with sample rate configurable signal processing | ||
Patent #
US 10,874,336 B2
Filed 10/12/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Medical device inserters and processes of inserting and using medical devices | ||
Patent #
US 10,881,341 B1
Filed 09/23/2020
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Medical device inserters and processes of inserting and using medical devices | ||
Patent #
US 10,881,340 B2
Filed 01/15/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Systems and methods for display device and sensor electronics unit communication | ||
Patent #
US 10,881,335 B2
Filed 08/29/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Displays for a medical device | ||
Patent #
US 10,881,355 B2
Filed 06/15/2020
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
TRANSCUTANEOUS ANALYTE SENSOR | ||
Patent #
US 20060036143A1
Filed 03/10/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
BIOLOGICAL FUEL CELL AND METHODS | ||
Patent #
US 20060159981A1
Filed 03/28/2006
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Silicone based membranes for use in implantable glucose sensors | ||
Patent #
US 20060258761A1
Filed 04/14/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 20050043598A1
Filed 08/22/2003
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Biointerface membranes incorporating bioactive agents | ||
Patent #
US 20050031689A1
Filed 05/10/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte measuring device | ||
Patent #
US 20050033132A1
Filed 05/14/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 20050027181A1
Filed 08/01/2003
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 20050027180A1
Filed 08/01/2003
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 20050027463A1
Filed 08/01/2003
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Rolled electrode array and its method for manufacture | ||
Patent #
US 20050051427A1
Filed 07/21/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Electrochemical sensors including electrode systems with increased oxygen generation | ||
Patent #
US 20050051440A1
Filed 07/21/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Increasing bias for oxygen production in an electrode system | ||
Patent #
US 20050056552A1
Filed 07/21/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Device and method for determining analyte levels | ||
Patent #
US 6,862,465 B2
Filed 07/27/2001
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Silicone composition for biocompatible membrane | ||
Patent #
US 20050090607A1
Filed 10/28/2003
|
Current Assignee
DECOM INC.
|
Original Assignee
DexCom Incorporated
|
Porous membranes for use with implantable devices | ||
Patent #
US 20050112169A1
Filed 08/22/2003
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
INTEGRATED DELIVERY DEVICE FOR CONTINUOUS GLUCOSE SENSOR | ||
Patent #
US 20050192557A1
Filed 02/26/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
Dexcom Retail BV
|
Method of making a transcutaneous electrochemical sensor | ||
Patent #
US 6,973,706 B2
Filed 03/31/2003
|
Current Assignee
Therasense Incorporated
|
Original Assignee
Therasense Incorporated
|
Membrane for use with implantable devices | ||
Patent #
US 6,702,857 B2
Filed 07/27/2001
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Membrane and electrode structure for implantable sensor | ||
Patent #
US 6,721,587 B2
Filed 02/15/2002
|
Current Assignee
Regents of the University of California
|
Original Assignee
Regents of the University of California
|
Device and method for determining analyte levels | ||
Patent #
US 6,741,877 B1
Filed 01/21/2000
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Implantable glucose sensor | ||
Patent #
US 6,815,186 B2
Filed 01/28/2002
|
Current Assignee
Arbmetrics LLC
|
Original Assignee
Implanted Biosystems Incorporated
|
Implantable enzyme-based monitoring systems adapted for long term use | ||
Patent #
US 6,512,939 B1
Filed 06/27/2000
|
Current Assignee
Medtronic Minimed Incorporated
|
Original Assignee
Medtronic Minimed Incorporated
|
Sensor head for use with implantable devices | ||
Patent #
US 20030032874A1
Filed 07/27/2001
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Subcutaneous glucose electrode | ||
Patent #
US 6,514,718 B2
Filed 11/29/2001
|
Current Assignee
Therasense Incorporated
|
Original Assignee
Therasense Incorporated
|
Multi-component polymeric networks containing poly(ethylene glycol) | ||
Patent #
US 6,528,584 B2
Filed 04/12/2001
|
Current Assignee
University of Akron
|
Original Assignee
University of Akron
|
Biocompatible medical articles and process for their production | ||
Patent #
US 20030059631A1
Filed 09/23/2002
|
Current Assignee
Bayer Materialscience AG
|
Original Assignee
Phylogenetix Laboratories Inc.
|
Implantable enzyme-based monitoring system having improved longevity due to improved exterior surfaces | ||
Patent #
US 20030065254A1
Filed 10/31/2002
|
Current Assignee
Alfred E. Mann Foundation For Scientific Research
|
Original Assignee
Alfred E. Mann Foundation For Scientific Research
|
Microstructured bilateral sensor | ||
Patent #
US 6,551,496 B1
Filed 03/06/2001
|
Current Assignee
YSI Incorporated
|
Original Assignee
YSI Incorporated
|
Nanoporous silicone resins having low dielectric constants | ||
Patent #
US 6,541,107 B1
Filed 10/25/1999
|
Current Assignee
Dow Inc.
|
Original Assignee
Dow Inc.
|
Polar solvent compatible polyethersiloxane elastomers | ||
Patent #
US 6,545,085 B2
Filed 10/05/2001
|
Current Assignee
Citibank South Dakota NA
|
Original Assignee
General Electric Company
|
Analyte monitoring device and methods of use | ||
Patent #
US 6,565,509 B1
Filed 09/21/2000
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Therasense Incorporated
|
Device for signal processing for measurement of physiological analytes | ||
Patent #
US 6,595,919 B2
Filed 02/27/2001
|
Current Assignee
LifeScan IP Holdings LLC
|
Original Assignee
Cygnus Inc.
|
Formulation and manipulation of databases of analyte and associated values | ||
Patent #
US 6,633,772 B2
Filed 08/10/2001
|
Current Assignee
LifeScan IP Holdings LLC
|
Original Assignee
Cygnus Inc.
|
Implantable glucose sensor | ||
Patent #
US 6,343,225 B1
Filed 09/14/1999
|
Current Assignee
Arbmetrics LLC
|
Original Assignee
Implanted Biosystems Incorporated
|
RETRIEVABLE BIOARTIFICIAL IMPLANTS HAVING DIMENSIONS ALLOWING RAPID DIFFUSION OF OXYGEN AND RAPID BIOLOGICAL RESPONSE TO PHYSIOLOGICAL CHANGE, PROCESSES FOR THEIR MANUFACTURE, AND METHODS FOR THEIR USE | ||
Patent #
US 6,372,244 B1
Filed 08/25/2000
|
Current Assignee
Islet Sheet Medical LLC
|
Original Assignee
ISLET SHEET MEDICAL INC.
|
Implanted sensor processing system and method for processing implanted sensor output | ||
Patent #
US 6,400,974 B1
Filed 06/29/2000
|
Current Assignee
Senseonics Incorporated
|
Original Assignee
Sensors For Medicine and Science Incorporated
|
Enzyme electrode sensor and manufacturing method thereof | ||
Patent #
US 6,413,396 B1
Filed 02/04/2000
|
Current Assignee
Electronics and Telecommunications Research Institute
|
Original Assignee
Electronics and Telecommunications Research Institute
|
Implantable enzyme-based monitoring systems having improved longevity due to improved exterior surfaces | ||
Patent #
US 6,477,395 B2
Filed 09/14/1999
|
Current Assignee
Medtronic Minimed Incorporated
|
Original Assignee
Medtronic Minimed Incorporated
|
Prostheses for plastic reconstruction with improved hydrophilicity properties, and method for obtaining them | ||
Patent #
US 20020193885A1
Filed 03/25/2002
|
Current Assignee
Association Pour Les Transferts De Technologies Du Mans
|
Original Assignee
ASSOC. POUR LES TRANSFERTS DE TECHNOLOGIES DU MANS
|
Device for monitoring changes in analyte concentration | ||
Patent #
US 6,212,416 B1
Filed 05/22/1998
|
Current Assignee
LEGACY GOOD SAMARITAN HOSPITAL AND MEDICAL CENTER
|
Original Assignee
Good Samaritan Hospital Medical Center
|
Implantable device containing GDNF secreting cells for treating nerve damage and methods of use | ||
Patent #
US 6,015,572 A
Filed 05/30/1995
|
Current Assignee
Amgen Inc.
|
Original Assignee
Amgen Inc.
|
Implantable biocompatable immunoisolatory vehicle for delivery of selected therapeutic products | ||
Patent #
US 6,083,523 A
Filed 09/04/1998
|
Current Assignee
Neurotech S.A.
|
Original Assignee
Brown University
|
Optical oxidative enzyme-based sensors | ||
Patent #
US 6,107,083 A
Filed 08/21/1998
|
Current Assignee
Siemens Healthcare Diagnostics Incorporated
|
Original Assignee
Bayer Corporation
|
Implantable enzyme-based monitoring systems having improved longevity due to improved exterior surfaces | ||
Patent #
US 6,119,028 A
Filed 10/20/1997
|
Current Assignee
Alfred E. Mann Foundation For Scientific Research
|
Original Assignee
Alfred E. Mann Foundation For Scientific Research
|
Implantable sensor and system for measurement and control of blood constituent levels | ||
Patent #
US 6,122,536 A
Filed 06/23/1998
|
Current Assignee
Animas Corporation
|
Original Assignee
Animas Corporation
|
Chemical signal-impermeable mask | ||
Patent #
US 6,141,573 A
Filed 08/04/1998
|
Current Assignee
Animas Technologies LLC
|
Original Assignee
Cygnus Inc.
|
Polyurethane/polyurea compositions containing silicone for biosensor membranes | ||
Patent #
US 5,882,494 A
Filed 08/28/1995
|
Current Assignee
Minimed Inc.
|
Original Assignee
Minimed Inc.
|
Diffusional implantable delivery system | ||
Patent #
US 5,972,369 A
Filed 03/30/1998
|
Current Assignee
ALZA Corporation
|
Original Assignee
ALZA Corporation
|
Implantable system for cell growth control | ||
Patent #
US 5,964,745 A
Filed 03/18/1996
|
Current Assignee
US MED
|
Original Assignee
US MED
|
Glucose sensor | ||
Patent #
US 5,964,993 A
Filed 12/19/1996
|
Current Assignee
Tenax Therapeutics Inc.
|
Original Assignee
Implanted Biosystems Incorporated
|
Method for increasing the service life of an implantable sensor | ||
Patent #
US 5,985,129 A
Filed 04/28/1992
|
Current Assignee
Regents of the University of California
|
Original Assignee
Regents of the University of California
|
Device and method for determining analyte levels | ||
Patent #
US 6,001,067 A
Filed 03/04/1997
|
Current Assignee
DexCom Incorporated
|
Original Assignee
Markwell Medical Institute Inc.
|
Three-layered membrane for use in an electrochemical sensor system | ||
Patent #
US 5,773,270 A
Filed 05/17/1994
|
Current Assignee
Chiron Corporation
|
Original Assignee
Chiron Corporation
|
Method for producing improved sensor | ||
Patent #
US 5,783,054 A
Filed 04/09/1997
|
Current Assignee
BIOSENSOR ENTERPRISES LLC
|
Original Assignee
University of Sydney, Australian Membrane and Biotechnology Research Institute
|
Silicon-containing biocompatible membranes | ||
Patent #
US 5,777,060 A
Filed 09/26/1996
|
Current Assignee
Minimed Inc.
|
Original Assignee
Minimed Inc.
|
Biosensor | ||
Patent #
US 5,795,774 A
Filed 07/10/1997
|
Current Assignee
NEC Corporation
|
Original Assignee
NEC Corporation
|
Electrode assembly for assaying glucose | ||
Patent #
US 5,804,048 A
Filed 08/15/1996
|
Current Assignee
Segars California Partners LP
|
Original Assignee
VIA MEDICAL CORPORATION
|
Thickening silicones with elastomeric silicone polyethers | ||
Patent #
US 5,811,487 A
Filed 12/16/1996
|
Current Assignee
Dow Inc.
|
Original Assignee
Dow Inc.
|
Implantable non-invasive rate-adjustable pump | ||
Patent #
US 5,820,589 A
Filed 04/30/1996
|
Current Assignee
Medtronic Incorporated
|
Original Assignee
Medtronic Incorporated
|
Breathable liquid elimination analysis | ||
Patent #
US 5,590,651 A
Filed 01/17/1995
|
Current Assignee
Temple University of The Commonwealth System of Higher Education
|
Original Assignee
Temple University of The Commonwealth System of Higher Education
|
Optical glucose sensor | ||
Patent #
US 5,605,152 A
Filed 07/18/1994
|
Current Assignee
Medtronic Minimed Incorporated
|
Original Assignee
Minimed Inc.
|
Microbiosensor used in-situ | ||
Patent #
US 5,611,900 A
Filed 07/20/1995
|
Current Assignee
Michigan State University
|
Original Assignee
Michigan State University
|
Electrochemical sensors | ||
Patent #
US 5,494,562 A
Filed 06/27/1994
|
Current Assignee
Siemens Healthcare Diagnostics Incorporated
|
Original Assignee
CIBA Vision Corporation
|
Surface-modifying endgroups for biomedical polymers | ||
Patent #
US 5,589,563 A
Filed 04/01/1994
|
Current Assignee
Polymer Technology Group Inc.
|
Original Assignee
Polymer Technology Group Inc.
|
Enhancing the hydrophilicity of silicone polymers | ||
Patent #
US 5,397,848 A
Filed 05/21/1993
|
Current Assignee
Abbott Medical Optics Incorporated
|
Original Assignee
Allergan Inc. Canada
|
Copolymers and non-porous, semi-permeable membrane thereof and its use for permeating molecules of predetermined molecular weight range | ||
Patent #
US 5,428,123 A
Filed 04/23/1993
|
Current Assignee
Polymer Technology Group Inc.
|
Original Assignee
Polymer Technology Group Inc.
|
Implantable catheter with electrical pulse nerve stimulators and drug delivery system | ||
Patent #
US 5,458,631 A
Filed 03/22/1994
|
Current Assignee
Ravi Xavier
|
Original Assignee
Ravi Xavier
|
Acrylic copolymer membranes for biosensors | ||
Patent #
US 5,476,094 A
Filed 11/15/1993
|
Current Assignee
Disetronic Licensing Ag
|
Original Assignee
Eli Lilly and Company
|
Hydrophilic polyurethane membranes for electrochemical glucose sensors | ||
Patent #
US 5,322,063 A
Filed 10/04/1991
|
Current Assignee
Disetronic Licensing Ag
|
Original Assignee
Eli Lilly and Company
|
Polysiloxane-polylactone block copolymers | ||
Patent #
US 5,235,003 A
Filed 08/31/1990
|
Current Assignee
TC1 LLC
|
Original Assignee
Thoratec Laboratories Corp.
|
Noninvasive blood glucose measuring device | ||
Patent #
US 5,140,985 A
Filed 10/21/1991
|
Current Assignee
Jon M. Schroeder, Joseph F. Long
|
Original Assignee
Jon M. Schroeder, Joseph F. Long
|
Enzyme electrodes and improvements in the manufacture thereof | ||
Patent #
US 5,160,418 A
Filed 07/18/1989
|
Current Assignee
CAMBRIDGE LIFE SCIENCES PLC
|
Original Assignee
CAMBRIDGE LIFE SCIENCES PLC
|
Biological fluid measuring device | ||
Patent #
US 4,994,167 A
Filed 07/07/1988
|
Current Assignee
DexCom Incorporated
|
Original Assignee
Markwell Medical Institute Inc.
|
Polarographic method for measuring both analyte and oxygen with the same detecting electrode of an electroenzymatic sensor | ||
Patent #
US 5,030,333 A
Filed 10/14/1986
|
Current Assignee
Childrens Hospital Medical Center
|
Original Assignee
Childrens Hospital Medical Center
|
Two-dimensional diffusion glucose substrate sensing electrode | ||
Patent #
US 4,890,620 A
Filed 02/17/1988
|
Current Assignee
Regents of the University of California
|
Original Assignee
Regents of the University of California
|
Polysiloxane-polylactone block copolymers | ||
Patent #
US 4,963,595 A
Filed 12/22/1988
|
Current Assignee
TC1 LLC
|
Original Assignee
Thoratec Laboratories Corp.
|
Immobilized enzyme electrodes | ||
Patent #
US 4,970,145 A
Filed 01/20/1988
|
Current Assignee
CAMBRIDGE LIFE SCIENCES PLC A CORP. OF GREAT BRITAIN
|
Original Assignee
CAMBRIDGE LIFE SCIENCES PLC
|
Block-graft copolymer | ||
Patent #
US 4,803,243 A
Filed 03/25/1987
|
Current Assignee
Shin-Etsu Chemical Company Limited
|
Original Assignee
Shin-Etsu Chemical Company Limited
|
Segmented polyether polyurethane | ||
Patent #
US 4,849,458 A
Filed 06/17/1988
|
Current Assignee
Innovative Technologies Incorporated
|
Original Assignee
Matrix Medical LLC
|
Polymer systems suitable for blood-contacting surfaces of a biomedical device, and methods for forming | ||
Patent #
US 4,861,830 A
Filed 06/22/1987
|
Current Assignee
TC1 LLC
|
Original Assignee
Th. Goldschmidt AG
|
Implantable gas-containing biosensor and method for measuring an analyte such as glucose | ||
Patent #
US 4,721,677 A
Filed 05/07/1987
|
Current Assignee
Childrens Hospital Medical Center
|
Original Assignee
Childrens Hospital Medical Center
|
Method and membrane applicable to implantable sensor | ||
Patent #
US 4,650,547 A
Filed 12/20/1985
|
Current Assignee
Regents of the University of California
|
Original Assignee
Regents of the University of California
|
Implantable gas-containing biosensor and method for measuring an analyte such as glucose | ||
Patent #
US 4,680,268 A
Filed 09/18/1985
|
Current Assignee
Childrens Hospital Medical Center
|
Original Assignee
Childrens Hospital Medical Center
|
Test device, method of manufacturing same and method of determining a component in a sample | ||
Patent #
US 4,689,309 A
Filed 09/30/1985
|
Current Assignee
Miles Laboratories Inc.
|
Original Assignee
Miles Laboratories Inc.
|
Polycarbonate-polyether-copolymer membrane | ||
Patent #
US 4,686,044 A
Filed 12/09/1985
|
Current Assignee
Akzo Nobel N.V.
|
Original Assignee
Akzo Nobel N.V.
|
Complete glucose monitoring system with an implantable, telemetered sensor module | ||
Patent #
US 4,703,756 A
Filed 05/06/1986
|
Current Assignee
Regents of the University of California
|
Original Assignee
Regents of the University of California
|
Implantable glucose sensor | ||
Patent #
US 4,431,004 A
Filed 10/27/1981
|
Current Assignee
Ennis C. Layne, Samuel P. Bessman, Lyell J. Thomas
|
Original Assignee
Ennis C. Layne, Samuel P. Bessman, Lyell J. Thomas
|
Method and membrane applicable to implantable sensor | ||
Patent #
US 4,484,987 A
Filed 05/19/1983
|
Current Assignee
Regents of the University of California
|
Original Assignee
Regents of the University of California
|
Enzyme electrode membrane | ||
Patent #
US 4,415,666 A
Filed 11/05/1981
|
Current Assignee
Miles Laboratories Inc.
|
Original Assignee
Miles Laboratories Inc.
|
Multilayer enzyme electrode membrane | ||
Patent #
US 4,418,148 A
Filed 11/05/1981
|
Current Assignee
Miles Laboratories Inc.
|
Original Assignee
Miles Laboratories Inc.
|
Hydrophilic contact lens made from polysiloxanes which are thermally bonded to polymerizable groups and which contain hydrophilic sidechains | ||
Patent #
US 4,260,725 A
Filed 12/10/1979
|
Current Assignee
Bausch Lomb Incorporated
|
Original Assignee
Bausch Lomb Incorporated
|
Membrane for enzyme electrodes | ||
Patent #
US 4,073,713 A
Filed 07/26/1976
|
Current Assignee
The Yellow Springs Instrument Company Inc.
|
Original Assignee
THE YELLOW SPRINGS INSTRUMENT COMPANY INC.
|
Polarographic analysis of cholesterol and other macromolecular substances | ||
Patent #
US 4,040,908 A
Filed 03/12/1976
|
Current Assignee
Childrens Hospital Medical Center
|
Original Assignee
Childrens Hospital Medical Center
|
Membrane for enzyme electrodes | ||
Patent #
US 3,979,274 A
Filed 09/24/1975
|
Current Assignee
The Yellow Springs Instrument Company Inc.
|
Original Assignee
THE YELLOW SPRINGS INSTRUMENT COMPANY INC.
|
21 Claims
-
1. An electrochemical glucose sensor for determining a presence or a concentration of glucose in a fluid, the sensor comprising:
-
a multilayer membrane system comprising a cell impermeable domain that is substantially impermeable to cells, a resistance domain configured to restrict a flow of the glucose therethrough, and an enzyme domain comprising an enzyme that reacts with the glucose in the fluid as it passes though the enzyme domain; and a working electrode comprising a conductive material, wherein the working electrode is configured to measure a product of a reaction of the enzyme with the glucose, wherein the enzyme domain, the resistance domain, and the cell impermeable domain each comprise a polymer material with a higher oxygen solubility than an oxyhydrocarbon polymer and wherein each of the enzyme domain, the resistance domain, and the cell impermeable domain is configured to be permeable to the glucose. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
-
-
15. An electrochemical glucose sensor for determining a presence or a concentration of glucose in a fluid, the glucose sensor comprising:
-
a membrane system comprising; an enzyme domain comprising an enzyme that reacts with the glucose in the fluid as it passes through the enzyme domain; and a resistance domain configured to partially restrict a flow of the glucose therethrough, wherein the resistance domain is located more distal to the working electrode than the enzyme domain; a cell impermeable domain that is substantially impermeable to cells; and a working electrode, wherein the working electrode is configured to measure a product of a reaction of the enzyme with the glucose, wherein the resistance domain and the cell impermeable domain each comprise a silicone polymer blended with a hydrophilic polymer and are configured to be at least partially permeable to the glucose. - View Dependent Claims (16, 17, 18, 19, 20, 21)
-
1 Specification
This application claims the benefit of priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 60/490,009, filed Jul. 25, 2003, the contents of which are hereby incorporated by reference in their entirety.
The present invention relates generally to systems and methods for increasing oxygen availability in implantable devices.
Electrochemical sensors are useful in chemistry and medicine to determine the presence or concentration of a biological analyte. Such sensors are useful, for example, to monitor glucose in diabetic patients and lactate during critical care events.
Diabetes mellitus is a disorder in which the pancreas cannot create sufficient insulin (Type I or insulin dependent) and/or in which insulin is not effective (Type 2 or non-insulin dependent). In the diabetic state, the victim suffers from high blood sugar, which causes an array of physiological derangements (kidney failure, skin ulcers, or bleeding into the vitreous of the eye) associated with the deterioration of small blood vessels. A hypoglycemic reaction (low blood sugar) is induced by an inadvertent overdose of insulin, or after a normal dose of insulin or glucose-lowering agent accompanied by extraordinary exercise or insufficient food intake.
Conventionally, a diabetic person carries a self-monitoring blood glucose (SMBG) monitor, which typically utilizes uncomfortable finger pricking methods. Due to the lack of comfort and convenience, a diabetic normally only measures his or her glucose level two to four times per day. Unfortunately, these time intervals are spread so far apart that the diabetic likely finds out too late, sometimes incurring dangerous side effects, of a hyperglycemic or hypoglycemic condition. In fact, it is not only unlikely that a diabetic will take a timely SMBG value, but additionally the diabetic will not know if their blood glucose value is going up (higher) or down (lower) based on conventional methods.
Consequently, a variety of transdermal and implantable electrochemical sensors are being developed for continuously detecting and/or quantifying blood glucose values. Many implantable glucose sensors suffer from complications within the body and provide only short-term or less-than-accurate sensing of blood glucose. Similarly, transdermal sensors have problems in accurately sensing and reporting back glucose values continuously over extended periods of time. Some efforts have been made to obtain blood glucose data from implantable devices and retrospectively determine blood glucose trends for analysis; however these efforts do not aid the diabetic in determining real-time blood glucose information. Some efforts have also been made to obtain blood glucose data from transdermal devices for prospective data analysis, however similar problems have been observed.
Sensors that can provide accurate, real-time information under ischemic conditions are therefore desirable.
Accordingly, in a first embodiment, an electrochemical sensor for determining a presence or a concentration of an analyte in a fluid is provided, the sensor including a membrane system including an enzyme domain including an enzyme that reacts with the analyte in the fluid as it passes through the enzyme domain; and a working electrode including a conductive material, wherein the working electrode is configured to measure a product of a reaction of the enzyme with the analyte, wherein the membrane system includes a polymer material with a high oxygen solubility.
In an aspect of the first embodiment, the enzyme domain includes a polymer material with a high oxygen solubility.
In an aspect of the first embodiment, the polymer material is selected from the group consisting of silicone, fluorocarbon, and perfluorocarbon.
In an aspect of the first embodiment, the sensor further includes a resistance domain configured to restrict a flow of the analyte therethrough, wherein the resistance domain is located more distal to the working electrode than the enzyme domain, and wherein the resistance domain includes a polymer material with a high oxygen solubility.
In an aspect of the first embodiment, the resistance domain includes a polymer material selected from the group consisting of silicone, fluorocarbon, and perfluorocarbon.
In an aspect of the first embodiment, the sensor further includes a cell impermeable domain that is substantially impermeable to cells, wherein the cell impermeable domain is located more distal to the working electrode than the enzyme domain, and wherein the cell impermeable domain includes a polymer material with a high oxygen solubility.
In an aspect of the first embodiment, the cell impermeable domain includes a polymer material selected from the group consisting of silicone, fluorocarbon, and perfluorocarbon.
In an aspect of the first embodiment, the sensor further includes a cell disruptive domain that includes a substantially porous structure, wherein the cell disruptive domain is located more distal to the working electrode than the enzyme domain, and wherein the cell disruptive domain includes a polymer material with high oxygen solubility.
In an aspect of the first embodiment, the cell impermeable domain includes a polymer material selected from the group consisting of silicone, fluorocarbon, and perfluorocarbon.
In an aspect of the first embodiment, the sensor further includes an interference domain configured to limit or block interfering species, wherein the interference domain is located more proximal to the working electrode than the enzyme domain, and wherein the interference domain includes a polymer material with a high oxygen solubility.
In an aspect of the first embodiment, the interference domain includes a polymer material selected from the group consisting of silicone, fluorocarbon, and perfluorocarbon.
In an aspect of the first embodiment, the sensor further includes an electrolyte domain configured to provide hydrophilicity at the working electrode, wherein the electrolyte domain is located more proximal to the working electrode than the enzyme domain, and wherein the electrolyte domain includes a polymer material with a high oxygen solubility.
In an aspect of the first embodiment, the electrolyte domain includes a polymer material selected from the group consisting of silicone, fluorocarbon, and perfluorocarbon.
In a second embodiment, an analyte sensing device configured for implantation into a tissue of a host is provided, the device including an oxygen-utilizing source; a membrane system configured to provide at least one function selected from the group consisting of protection of the device from a biological environment; diffusion resistance of an analyte; a catalyst for enabling an enzymatic reaction; and limitation of interfering species; wherein the membrane system includes a polymer material with a high oxygen solubility, wherein the membrane system is adjacent to the oxygen-utilizing source.
In an aspect of the second embodiment, the oxygen-utilizing source includes an enzyme.
In an aspect of the second embodiment, the membrane system includes the polymer material with the high oxygen solubility, wherein the polymer material is substantially continuously situated between the enzyme and the tissue.
In an aspect of the second embodiment, the oxygen-utilizing source includes an electroactive surface.
In an aspect of the second embodiment, the membrane system includes the polymer material with the high oxygen solubility, wherein the polymer material is substantially continuously situated between the electroactive surface and the tissue.
In an aspect of the second embodiment, the oxygen-utilizing source includes cells.
In an aspect of the second embodiment, the membrane system includes the polymer material with the high oxygen solubility, wherein the polymer material is substantially continuously situated between the cells and the tissue.
In an aspect of the second embodiment, the polymer material is selected from the group consisting of silicone, fluorocarbon, and perfluorocarbon.
The following description and examples illustrate some exemplary embodiments of the disclosed invention in detail. Those of skill in the art will recognize that there are numerous variations and modifications of this invention that are encompassed by its scope. Accordingly, the description of a certain exemplary embodiment should not be deemed to limit the scope of the present invention.
Definitions
In order to facilitate an understanding of the preferred embodiments, a number of terms are defined below.
The term “analyte” as used herein is a broad term and is used in its ordinary sense, including, without limitation, to refer to a substance or chemical constituent in a biological fluid (for example, blood, interstitial fluid, cerebral spinal fluid, lymph fluid or urine) that can be analyzed. Analytes can include naturally occurring substances, artificial substances, metabolites, and/or reaction products. In some embodiments, the analyte for measurement by the sensing regions, devices, and methods is glucose. However, other analytes are contemplated as well, including but not limited to acarboxyprothrombin; acylcamitine; adenine phosphoribosyl transferase; adenosine deaminase; albumin; alpha-fetoprotein; amino acid profiles (arginine (Krebs cycle), histidine/urocanic acid, homocysteine, phenylalanine/tyrosine, tryptophan); andrenostenedione; antipyrine; arabinitol enantiomers; arginase; benzoylecgonine (cocaine); biotinidase; biopterin; c-reactive protein; carnitine; carnosinase; CD4; ceruloplasmin; chenodeoxycholic acid; chloroquine; cholesterol; cholinesterase; conjugated 1-β hydroxy-cholic acid; cortisol; creatine kinase; creatine kinase MM isoenzyme; cyclosporin A; d-penicillamine; de-ethylchloroquine; dehydroepiandrosterone sulfate; DNA (acetylator polymorphism, alcohol dehydrogenase, alpha 1-antitrypsin, cystic fibrosis, Duchenne/Becker muscular dystrophy, glucose-6-phosphate dehydrogenase, hemoglobin A, hemoglobin S, hemoglobin C, hemoglobin D, hemoglobin E, hemoglobin F, D-Punjab, beta-thalassemia, hepatitis B virus, HCMV, HIV-1, HTLV-1, Leber hereditary optic neuropathy, MCAD, RNA, PKU, Plasmodium vivax, sexual differentiation, 21-deoxycortisol); desbutylhalofantrine; dihydropteridine reductase; diptheria/tetanus antitoxin; erythrocyte arginase; erythrocyte protoporphyrin; esterase D; fatty acids/acylglycines; free β-human chorionic gonadotropin; free erythrocyte porphyrin; free thyroxine (FT4); free tri-iodothyronine (FT3); fumarylacetoacetase; galactose/gal-1-phosphate; galactose-1-phosphate uridyltransferase; gentamicin; glucose-6-phosphate dehydrogenase; glutathione; glutathione perioxidase; glycocholic acid; glycosylated hemoglobin; halofantrine; hemoglobin variants; hexosaminidase A; human erythrocyte carbonic anhydrase I; 17-alpha-hydroxyprogesterone; hypoxanthine phosphoribosyl transferase; immunoreactive trypsin; lactate; lead; lipoproteins ((a), B/A-1, β); lysozyme; mefloquine; netilmicin; phenobarbitone; phenytoin; phytanic/pristanic acid; progesterone; prolactin; prolidase; purine nucleoside phosphorylase; quinine; reverse tri-iodothyronine (rT3); selenium; serum pancreatic lipase; sissomicin; somatomedin C; specific antibodies (adenovirus, anti-nuclear antibody, anti-zeta antibody, arbovirus, Aujeszky'"'"'s disease virus, dengue virus, Dracunculus medinensis, Echinococcus granulosus, Entamoeba histolytica, enterovirus, Giardia duodenalisa, Helicobacter pylori, hepatitis B virus, herpes virus, HIV-1, IgE (atopic disease), influenza virus, Leishmania donovani, leptospira, measles/mumps/rubella, Mycobacterium leprae, Mycoplasma pneumoniae, Myoglobin, Onchocerca volvulus, parainfluenza virus, Plasmodium falciparum, poliovirus, Pseudomonas aeruginosa, respiratory syncytial virus, rickettsia (scrub typhus), Schistosoma mansoni, Toxoplasma gondii, Trepenoma pallidium, Trypanosoma cruzi/rangeli, vesicular stomatis virus, Wuchereria bancrofti, yellow fever virus); specific antigens (hepatitis B virus, HIV-1); succinylacetone; sulfadoxine; theophylline; thyrotropin (TSH); thyroxine (T4); thyroxine-binding globulin; trace elements; transferrin; UDP-galactose-4-epimerase; urea; uroporphyrinogen I synthase; vitamin A; white blood cells; and zinc protoporphyrin. Salts, sugar, protein, fat, vitamins and hormones naturally occurring in blood or interstitial fluids can also constitute analytes in certain embodiments. The analyte can be naturally present in the biological fluid or endogenous, for example, a metabolic product, a hormone, an antigen, an antibody, and the like. Alternatively, the analyte can be introduced into the body or exogenous, for example, a contrast agent for imaging, a radioisotope, a chemical agent, a fluorocarbon-based synthetic blood, or a drug or pharmaceutical composition, including but not limited to insulin; ethanol; cannabis (marijuana, tetrahydrocannabinol, hashish); inhalants (nitrous oxide, amyl nitrite, butyl nitrite, chlorohydrocarbons, hydrocarbons); cocaine (crack cocaine); stimulants (amphetamines, methamphetamines, Ritalin, Cylert, Preludin, Didrex, PreState, Voranil, Sandrex, Plegine); depressants (barbituates, methaqualone, tranquilizers such as Valium, Librium, Miltown, Serax, Equanil, Tranxene); hallucinogens (phencyclidine, lysergic acid, mescaline, peyote, psilocybin); narcotics (heroin, codeine, morphine, opium, meperidine, Percocet, Percodan, Tussionex, Fentanyl, Darvon, Talwin, Lomotil); designer drugs (analogs of fentanyl, meperidine, amphetamines, methamphetamines, and phencyclidine, for example, Ecstasy); anabolic steroids; and nicotine. The metabolic products of drugs and pharmaceutical compositions are also contemplated analytes. Analytes such as neurochemicals and other chemicals generated within the body can also be analyzed, such as, for example, ascorbic acid, uric acid, dopamine, noradrenaline, 3-methoxytyramine (3MT), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 5-hydroxytryptamine (5HT), and 5-hydroxyindoleacetic acid (FHIAA).
The terms “operable connection,” “operably connected,” and “operably linked” as used herein are broad terms and are used in their ordinary sense, including, without limitation, one or more components linked to another component(s) in a manner that allows transmission of signals between the components. For example, one or more electrodes can be used to detect the amount of analyte in a sample and convert that information into a signal; the signal can then be transmitted to a circuit. In this case, the electrode is “operably linked” to the electronic circuitry.
The term “host” as used herein is a broad term and is used in its ordinary sense, including, without limitation, mammals, particularly humans.
The terms “electrochemically reactive surface” and “electroactive surface” as used herein are broad terms and are used in their ordinary sense, including, without limitation, the surface of an electrode where an electrochemical reaction takes place. As one example, a working electrode measures hydrogen peroxide produced by the enzyme catalyzed reaction of the analyte being detected reacts creating an electric current (for example, detection of glucose analyte utilizing glucose oxidase produces H2O2 as a by product, H2O2 reacts with the surface of the working electrode producing two protons (2H+), two electrons (2e−) and one molecule of oxygen (O2) which produces the electronic current being detected). In the case of the counter electrode, a reducible species, for example, O2 is reduced at the electrode surface in order to balance the current being generated by the working electrode.
The term “sensing region” as used herein is a broad term and is used in its ordinary sense, including, without limitation, the region of a monitoring device responsible for the detection of a particular analyte. The sensing region generally comprises a non-conductive body, a working electrode, a reference electrode, and/or a counter electrode (optional) passing through and secured within the body forming electrochemically reactive surfaces on the body, an electronic connective means at another location on the body, and a multi-domain membrane affixed to the body and covering the electrochemically reactive surface.
The terms “raw data stream” and “data stream,” as used herein, are broad terms and are used in their ordinary sense, including, without limitation, an analog or digital signal directly related to the measured glucose concentration from the glucose sensor. In one example, the raw data stream is digital data in “counts” converted by an A/D converter from an analog signal (for example, voltage or amps) representative of a glucose concentration. The terms broadly encompass a plurality of time spaced data points from a substantially continuous glucose sensor, which comprises individual measurements taken at time intervals ranging from fractions of a second up to, for example, 1, 2, or 5 minutes or longer.
The term “counts,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, a unit of measurement of a digital signal. In one example, a raw data stream measured in counts is directly related to a voltage (for example, converted by an A/D converter), which is directly related to current from the working electrode. In another example, counter electrode voltage measured in counts is directly related to a voltage.
The term “electrical potential,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, the electrical potential difference between two points in a circuit which is the cause of the flow of a current.
The term “ischemia,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, local and temporary deficiency of blood supply due to obstruction of circulation to a part (for example, sensor). Ischemia can be caused by mechanical obstruction (for example, arterial narrowing or disruption) of the blood supply, for example.
The term “system noise,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, unwanted electronic or diffusion-related noise which can include Gaussian, motion-related, flicker, kinetic, or other white noise, for example.
The terms “signal artifacts” and “transient non-glucose related signal artifacts,” as used herein, are broad terms and are used in their ordinary sense, including, without limitation, signal noise that is caused by substantially non-glucose reaction rate-limiting phenomena, such as ischemia, pH changes, temperature changes, pressure, and stress, for example. Signal artifacts, as described herein, are typically transient and are characterized by higher amplitude than system noise.
The terms “low noise,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, noise that substantially decreases signal amplitude.
The terms “high noise” and “high spikes,” as used herein, are broad terms and are used in their ordinary sense, including, without limitation, noise that substantially increases signal amplitude.
The term “silicone composition” as used herein is a broad term and is used in its ordinary sense, including, without limitation, a composition of matter that comprises polymers having at least silicon and oxygen atoms in the backbone.
The phrase “distal to” as used herein is a broad term and is used in its ordinary sense, including, without limitation, the spatial relationship between various elements in comparison to a particular point of reference. For example, some embodiments of a device include a membrane system having a cell disruptive domain and a cell impermeable domain. If the sensor is deemed to be the point of reference and the cell disruptive domain is positioned farther from the sensor, then that domain is distal to the sensor.
The phrase “proximal to” as used herein is a broad term and is used in its ordinary sense, including, without limitation, the spatial relationship between various elements in comparison to a particular point of reference. For example, some embodiments of a device include a membrane system having a cell disruptive domain and a cell impermeable domain. If the sensor is deemed to be the point of reference and the cell impermeable domain is positioned nearer to the sensor, then that domain is proximal to the sensor.
The terms “interferants” and “interfering species,” as used herein, are broad terms and are used in their ordinary sense, including, but not limited to, effects and/or species that interfere with the measurement of an analyte of interest in a sensor to produce a signal that does not accurately represent the analyte measurement. In an electrochemical sensor, interfering species can include compounds with an oxidation potential that overlaps with that of the analyte to be measured.
As employed herein, the following abbreviations apply: Eq and Eqs (equivalents); mEq (milliequivalents); M (molar); mM (millimolar) μM (micromolar); N (Normal); mol (moles); mmol (millimoles); μmol (micromoles); nmol (nanomoles); g (grams); mg (milligrams); μg (micrograms); Kg (kilograms); L (liters); mL (milliliters); dL (deciliters); μL (microliters); cm (centimeters); mm (millimeters); μm (micrometers); nm (nanometers); h and hr (hours); min. (minutes); s and sec. (seconds); ° C. (degrees Centigrade).
Overview
Membrane systems of the preferred embodiments are suitable for use with implantable devices in contact with a biological fluid. For example, the membrane systems can be utilized with implantable devices such as devices for monitoring and determining analyte levels in a biological fluid, for example, glucose levels for individuals having diabetes. In some embodiments, the analyte-measuring device is a continuous device. Alternatively, the device can analyze a plurality of intermittent biological samples. The analyte-measuring device can use any method of analyte-measurement, including enzymatic, chemical, physical, electrochemical, spectrophotometric, polarimetric, calorimetric, radiometric, or the like.
Although some of the description that follows is directed at glucose-measuring devices, including the described membrane systems and methods for their use, these membrane systems are not limited to use in devices that measure or monitor glucose. These membrane systems are suitable for use in a variety of devices, including, for example, those that detect and quantify other analytes present in biological fluids (including, but not limited to, cholesterol, amino acids, alcohol, galactose, and lactate), cell transplantation devices (see, for example, U.S. Pat. Nos. 6,015,572, 5,964,745, and 6,083,523), drug delivery devices (see, for example, U.S. Pat. Nos. 5,458,631, 5,820,589, and 5,972,369), and the like. Preferably, implantable devices that include the membrane systems of the preferred embodiments are implanted in soft tissue, for example, abdominal, subcutaneous, and peritoneal tissues, the brain, the intramedullary space, and other suitable organs or body tissues.
In addition to the glucose-measuring device described below, the membrane systems of the preferred embodiments can be employed with a variety of known glucose measuring-devices. In some embodiments, the electrode system can be used with any of a variety of known in vivo analyte sensors or monitors, such as U.S. Pat. No. 6,001,067 to Shults et al.; U.S. Pat. No. 6,702,857 to Brauker et al.; U.S. Pat. No. 6,212,416 to Ward et al.; U.S. Pat. No. 6,119,028 to Schulman et al.; U.S. Pat. No. 6,400,974 to Lesho; U.S. Pat. No. 6,595,919 to Berner et al.; U.S. Pat. No. 6,141,573 to Kurnik et al.; U.S. Pat. No. 6,122,536 to Sun et al.; European Patent Application EP 1153571 to Varall et al.; U.S. Pat. No. 6,512,939 to Colvin et al.; U.S. Pat. No. 5,605,152 to Slate et al.; U.S. Pat. No. 4,431,004 to Bessman et al.; U.S. Pat. No. 4,703,756 to Gough et al.; U.S. Pat. No. 6,514,718 to Heller et al.; U.S. Pat. No. to 5,985,129 to Gough et al.; WO Patent Application Publication No. 04/021877 to Caduff; U.S. Pat. No. 5,494,562 to Maley et al.; U.S. Pat. No. 6,120,676 to Heller et al.; and U.S. Pat. No. 6,542,765 to Guy et al, each of which are incorporated in there entirety herein by reference. In general, it is understood that the disclosed embodiments are applicable to a variety of continuous glucose measuring device configurations.
In this embodiment, the electrode system 16 is operably connected to the sensor electronics (
The membrane system 18 of the preferred embodiments, which are described in more detail below with reference to
In some embodiments, the electrode system 16, which is located on or within the sensing region 14, is comprised of at least a working and a reference electrode with an insulating material disposed therebetween. In some alternative embodiments, additional electrodes can be included within the electrode system, for example, a three-electrode system (working, reference, and counter electrodes) and/or including an additional working electrode (which can be used to generate oxygen, measure an additional analyte, or can be configured as a baseline subtracting electrode, for example).
In the exemplary embodiment of
GOX+Glucose+O2→Gluconate+H2O2+reduced GOX
The change in H2O2 can be monitored to determine glucose concentration because for each glucose molecule metabolized, there is a proportional change in the product H2O2. Oxidation of H2O2 by the working electrode is balanced by reduction of ambient oxygen, enzyme generated H2O2, or other reducible species at the counter electrode. The H2O2 produced from the glucose oxidase reaction further reacts at the surface of working electrode and produces two protons (2H+), two electrons (2e−), and one oxygen molecule (O2). In such embodiments, because the counter electrode utilizes oxygen as an electron acceptor, the most likely reducible species for this system are oxygen or enzyme generated peroxide. There are two main pathways by which oxygen can be consumed at the counter electrode. These pathways include a four-electron pathway to produce hydroxide and a two-electron pathway to produce hydrogen peroxide. In addition to the counter electrode, oxygen is further consumed by the reduced glucose oxidase within the enzyme domain. Therefore, due to the oxygen consumption by both the enzyme and the counter electrode, there is a net consumption of oxygen within the electrode system. Theoretically, in the domain of the working electrode there is significantly less net loss of oxygen than in the region of the counter electrode. In addition, there is a close correlation between the ability of the counter electrode to maintain current balance and sensor function.
In general, in electrochemical sensors wherein an enzymatic reaction depends on oxygen as a co-reactant, depressed function or inaccuracy can be experienced in low oxygen environments, for example in vivo. Subcutaneously implanted devices are especially susceptible to transient ischemia that can compromise device function; for example, because of the enzymatic reaction required for an implantable amperometric glucose sensor, oxygen must be in excess over glucose in order for the sensor to effectively function as a glucose sensor. If glucose becomes in excess, the sensor turns into an oxygen sensitive device. In vivo, glucose concentration can vary from about one hundred times or more that of the oxygen concentration. Consequently, oxygen becomes a limiting reactant in the electrochemical reaction and when insufficient oxygen is provided to the sensor, the sensor is unable to accurately measure glucose concentration. Those skilled in the art interpret oxygen limitations resulting in depressed function or inaccuracy as a problem of availability of oxygen to the enzyme and/or counter electrode. Oxygen limitations can also be seen during periods of transient ischemia that occur, for example, under certain postures or when the region around the implanted sensor is compressed so that blood is forced out of the capillaries. Such ischemic periods observed in implanted sensors can last for many minutes or even an hour or longer.
A microprocessor 22 is the central control unit that houses EEPROM 23 and SRAM 24, and controls the processing of the sensor electronics. The alternative embodiments can utilize a computer system other than a microprocessor to process data as described herein. In some alternative embodiments, an application-specific integrated circuit (ASIC) can be used for some or all the sensor'"'"'s central processing. EEPROM 23 provides semi-permanent storage of data, storing data such as sensor ID and programming to process data signals (for example, programming for data smoothing such as described elsewhere herein). SRAM 24 is used for the system'"'"'s cache memory, for example for temporarily storing recent sensor data.
The battery 25 is operatively connected to the microprocessor 22 and provides the power for the sensor. In one embodiment, the battery is a Lithium Manganese Dioxide battery, however any appropriately sized and powered battery can be used. In some embodiments, a plurality of batteries can be used to power the system. Quartz Crystal 26 is operatively connected to the microprocessor 22 and maintains system time for the computer system.
The RF Transceiver 27 is operably connected to the microprocessor 22 and transmits the sensor data from the sensor to a receiver. Although a RF transceiver is shown here, some other embodiments can include a wired rather than wireless connection to the receiver. In yet other embodiments, the sensor can be transcutaneously connected via an inductive coupling, for example. The quartz crystal 28 provides the system time for synchronizing the data transmissions from the RF transceiver. The transceiver 27 can be substituted with a transmitter in one embodiment.
Although
The raw data stream 30 includes substantially smooth sensor output in some portions, however other portions exhibit erroneous or transient non-glucose related signal artifacts 32. Particularly, referring to the signal artifacts 32, it is believed that effects of local ischemia on prior art electrochemical sensors creates erroneous (non-glucose) signal values due to oxygen deficiencies either at the enzyme within the membrane system and/or at the counter electrode on the electrode surface.
In one situation, when oxygen is deficient relative to the amount of glucose, the enzymatic reaction is limited by oxygen rather than glucose. Thus, the output signal is indicative of the oxygen concentration rather than the glucose concentration, producing erroneous signals. Additionally, when an enzymatic reaction is rate-limited by oxygen, glucose is expected to build up in the membrane because it is not completely catabolized during the oxygen deficit. When oxygen is again in excess, there is also excess glucose due to the transient oxygen deficit. The enzyme rate then speeds up for a short period until the excess glucose is catabolized, resulting in spikes of non-glucose related increased sensor output. Accordingly, because excess oxygen (relative to glucose) is necessary for proper sensor function, transient ischemia can result in a loss of signal gain in the sensor data.
In another situation, oxygen deficiency can be seen at the counter electrode when insufficient oxygen is available for reduction, which thus affects the counter electrode in that it is unable to balance the current coming from the working electrode. When insufficient oxygen is available for the counter electrode, the counter electrode can be driven in its electrochemical search for electrons all the way to its most negative value, which can be ground, or 0.0 V, which causes the reference to shift, reducing the bias voltage such as is described in more detail below. In other words, a common result of ischemia is seen as a drop off in sensor current as a function of glucose concentration (for example, lower sensitivity). This occurs because the working electrode no longer oxidizes all of the H2O2 arriving at its surface because of the reduced bias. In some extreme circumstances, an increase in glucose can produce no increase in current or even a decrease in current.
In some situations, transient ischemia can occur at high glucose levels, wherein oxygen can become limiting to the enzymatic reaction, resulting in a non-glucose dependent downward trend in the data. In some situations, certain movements or postures taken by the patient can cause transient signal artifacts as blood is squeezed out of the capillaries, resulting in local ischemia, and causing non-glucose dependent signal artifacts. In some situations, oxygen can also become transiently limited due to contracture of tissues around the sensor interface. This is similar to the blanching of skin that can be observed when one puts pressure on it. Under such pressure, transient ischemia can occur in both the epidermis and subcutaneous tissue. Transient ischemia is common and well tolerated by subcutaneous tissue. However, such ischemic periods can cause an oxygen deficit in implanted devices that can last for many minutes or even an hour or longer.
Although some examples of the effects of transient ischemia on a prior art glucose sensor are described above, similar effects can be seen with analyte sensors that use alternative catalysts to detect other analytes, for example, amino acids (amino acid oxidase), alcohol (alcohol oxidase), galactose (galactose oxidase), lactate (lactate oxidase), and cholesterol (cholesterol oxidase), or the like.
In order to overcome the effects of transient ischemia, the membrane systems 18 of the preferred embodiments include materials with high oxygen solubility. These materials increase the local amount of oxygen to aid in compensating for local oxygen deficits during ischemic conditions. As a result, the membrane systems of the preferred embodiments enable analyte sensors and other devices such as cell transplantation devices to function in the subcutaneous space even during local transient ischemia.
The phrases “high oxygen solubility” and “high oxygen soluble” as used herein are broad phrases and are used in their ordinary sense, including, without limitation, a domain or material property that includes higher oxygen solubility than aqueous media so that it concentrates oxygen from the biological fluid surrounding the membrane system. In some preferred embodiments, a high oxygen solubility polymer has at least about 3× higher oxygen solubility than aqueous media, more preferably at least about 4×, 5×, or 6× higher oxygen solubility than aqueous media, and most preferably at least about 7×, 8×, 9×, 10× or more higher oxygen solubility than aqueous media. In one embodiment, high oxygen solubility is defined as having higher oxygen solubility than at least one of a hydrocarbonaceous polymer and an oxyhydrocarbon polymer (a hydrocarbonaceous polymer is a polymeric material consisting of carbon and hydrogen atoms and an oxyhydrocarbonaceous polymer is a polymeric material consisting of carbon, hydrogen, and oxygen atoms). Oxygen solubility can be measured using any known technique, for example by removing the oxygen from the polymer (namely, solution) via at least three Freeze-Pump-Thaw cycles and then measuring the resultant oxygen (for example, using a manometer).
Oxygen permeability (Dk) is calculated as diffusion multiplied by solubility. Oxygen Permeability is conveniently reported in units of Barrers (1 Barrer=10−10 cm3 O2 (STP) cm/cm2s cmHg). Insulating materials of preferred embodiments that have a high oxygen permeability typically have an oxygen permeability of from about 1 Barrer or less to about 1000 Barrers or more, preferably from about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 Barrers to about 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 550, 600, 650, 700, 750, 800, 850, 900, or 950 Barrers.
In one exemplary embodiment, the properties of silicone (and/or silicone compositions) inherently enable materials formed from silicone to act as a high oxygen solubility domain. Utilization of a high oxygen soluble material in an electrochemical sensor is advantageous because it is believed to dynamically retain high oxygen availability to oxygen-utilizing sources (for example, an enzyme and/or a counter electrode of an electrochemical cell).
As described below with reference to
The membrane systems of preferred embodiments are constructed of two or more domains. The multi-domain membrane can be formed from one or more distinct layers and can comprise the same or different materials. The term “domain” is a broad term and is used in its ordinary sense, including, without limitation, a single homogeneous layer or region that incorporates the combined functions one or more domains, or a plurality of layers or regions that each provide one or more of the functions of each of the various domains.
In some embodiments, the membrane system is formed as a homogeneous membrane, namely, a membrane having substantially uniform characteristics from one side of the membrane to the other. However, a membrane can have heterogeneous structural domains, for example, domains resulting from the use of block copolymers (for example, polymers in which different blocks of identical monomer units alternate with each other), but can be defined as homogeneous overall in that each of the above-described domains functions by the preferential diffusion of some substance through the homogeneous membrane.
In the preferred embodiments, one or more of the above-described domains are formed from high oxygen solubility material. Utilization of high oxygen solubility material is advantageous because it is believed to dynamically retain a higher amount of oxygen, which maintains higher oxygen availability to selected locations (for example, the enzyme and/or counter electrode). In some embodiments, the high oxygen soluble material includes silicones, fluorocarbons, perfluorocarbons, or the like. In one embodiment, one or more domains is/are formed from a silicone composition that allows the transport of glucose other such water-soluble molecules (for example, drugs), such as are described in more detail with reference to co-pending U.S. application Ser. No. 10/695,636 filed Oct. 28, 2003 and published as U.S. Application Publication No. 2005-0090607 and entitled, “SILICONE COMPOSITION FOR BIOCOMPATIBLE MEMBRANE,” the contents of which are hereby incorporated by reference in their entireties.
Cell Disruptive Domain
The cell disruptive domain 40 is positioned most distal to the implantable device and is designed to support tissue ingrowth, to disrupt contractile forces typically found in a foreign body capsule, to encourage vascularity within the membrane, and/or to disrupt the formation of a barrier cell layer. In one embodiment, the cell disruptive domain 40 has an open-celled configuration with interconnected cavities and solid portions, wherein the distribution of the solid portion and cavities of the cell disruptive domain includes a substantially co-continuous solid domain and includes more than one cavity in three dimensions substantially throughout the entirety of the first domain. Cells can enter into the cavities; however they cannot travel through or wholly exist within the solid portions. The cavities allow most substances to pass through, including, for example, cells, and molecules. U.S. Pat. No. 6,702,857, filed Jul. 27, 2001, and entitled “MEMBRANE FOR USE WITH IMPLANTABLE DEVICES” and U.S. patent application Ser. No. 10/647,065, filed Aug. 22, 2003, and entitled, “POROUS MEMBRANES FOR USE WITH IMPLANTABLE DEVICES” describe membranes having a cell disruptive domain.
The cell disruptive domain 40 is preferably formed from high oxygen soluble materials such as polymers formed from silicone, fluorocarbons, perfluorocarbons, or the like. In one embodiment, the cell disruptive domain is formed from a silicone composition with a non-silicon containing hydrophile such as such as polyethylene glycol, propylene glycol, pyrrolidone, esters, amides, carbonates, or polypropylene glycol covalently incorporated or grafted therein. In some alternative embodiments, the cell disruptive domain is formed from polyethylene-co-tetrafluoroethylene, polyolefin, polyester, polycarbonate, biostable polytetrafluoroethylene, homopolymers, copolymers, terpolymers of polytetrafluoroethylene, polyurethanes, polypropylene (PP), polyvinylchloride (PVC), polyvinylidene fluoride (PVDF), polybutylene terephthalate (PBT), polymethylmethacrylate (PMMA), polyether ether ketone (PEEK), polyurethanes, cellulosic polymers, polysulfones or block copolymers thereof including, for example, di-block, tri-block, alternating, random and graft copolymers.
In preferred embodiments, the thickness of the cell disruptive domain is from about 10 or less, 20, 30, 40, 50, 60, 70, 80, or 90 microns to about 1500, 2000, 2500, or 3000 or more microns. In more preferred embodiments, the thickness of the cell disruptive domain is from about 100, 150, 200 or 250 microns to about 1000, 1100, 1200, 1300, or 1400 microns. In even more preferred embodiments, the thickness of the cell disruptive domain is from about 300, 350, 400, 450, 500, or 550 microns to about 500, 550, 600, 650, 700, 750, 800, 850, or 900 microns.
The cell disruptive domain is optional and can be omitted when using an implantable device that does not prefer tissue ingrowth, for example, a short-lived device (for example, less than one day to about a week) or one that delivers tissue response modifiers.
Cell Impermeable Domain
The cell impermeable domain 42 is positioned less distal to the implantable device than the cell disruptive domain, and can be resistant to cellular attachment, impermeable to cells, and/or is composed of a biostable material. When the cell impermeable domain is resistant to cellular attachment (for example, attachment by inflammatory cells, such as macrophages, which are therefore kept a sufficient distance from other domains, for example, the enzyme domain), hypochlorite and other oxidizing species are short-lived chemical species in vivo, and biodegradation does not occur. Additionally, the materials preferred for forming this domain are resistant to the effects of these oxidative species and have thus been termed biodurable. See, for example, U.S. Pat. No. 6,702,857, filed Jul. 27, 2001, and entitled “MEMBRANE FOR USE WITH IMPLANTABLE DEVICES” and U.S. patent application Ser. No. 10/647,065, filed Aug. 22, 2003, and entitled, “POROUS MEMBRANES FOR USE WITH IMPLANTABLE DEVICES.”
The cell impermeable domain 42 is preferably formed from high oxygen soluble materials such as polymers formed from silicone, fluorocarbons, perfluorocarbons, or the like. In one embodiment, the cell impermeable domain is formed from a silicone composition with a hydrophile such as such as polyethylene glycol, propylene glycol, pyrrolidone, esters, amides, carbonates, or polypropylene glycol covalently incorporated or grafted therein. In some alternative embodiments, the cell impermeable domain is formed from copolymers or blends of copolymers with hydrophilic polymers such as polyvinylpyrrolidone (PVP), polyhydroxyethyl methacrylate, polyvinylalcohol, polyacrylic acid, polyethers such as polyethylene glycol, and block copolymers thereof, including, for example, di-block, tri-block, alternating, random and graft copolymers (block copolymers are discussed in U.S. Pat. Nos. 4,803,243 and 4,686,044).
In preferred embodiments, the thickness of the cell impermeable domain is from about 10 or 15 microns or less to about 125, 150, 175, or 200 microns or more. In more preferred embodiments, the thickness of the cell impermeable domain is from about 20, 25, 30, or 35 microns to about 65, 70, 75, 80, 85, 90, 95, or 100 microns. In even more preferred embodiments, the cell impermeable domain is from about 40 or 45 microns to about 50, 55, or 60 microns thick.
The cell disruptive domain 40 and cell impermeable domain 42 of the membrane system can be formed together as one unitary structure. Alternatively, the cell disruptive and cell impermeable domains 40, 42 of the membrane system can be formed as two layers mechanically or chemically bonded together.
Resistance Domain
The resistance domain 44 is situated more proximal to the implantable device relative to the cell disruptive domain. The resistance domain controls the flux of oxygen and other analytes (for example, glucose) to the underlying enzyme domain. As described in more detail elsewhere herein, there exists a molar excess of glucose relative to the amount of oxygen in blood; that is, for every free oxygen molecule in extracellular fluid, there are typically more than 100 glucose molecules present (see Updike et al., Diabetes Care 5:207-21(1982)). However, an immobilized enzyme-based sensor employing oxygen as cofactor is supplied with oxygen in non-rate-limiting excess in order to respond linearly to changes in glucose concentration, while not responding to changes in oxygen tension. More specifically, when a glucose-monitoring reaction is oxygen-limited, linearity is not achieved above minimal concentrations of glucose. Without a semipermeable membrane situated over the enzyme domain to control the flux of glucose and oxygen, a linear response to glucose levels can be obtained only up to about 40 mg/dL. However, in a clinical setting, a linear response to glucose levels is desirable up to at least about 500 mg/dL.
The resistance domain 44 includes a semipermeable membrane that controls the flux of oxygen and glucose to the underlying enzyme domain 46, preferably rendering oxygen in non-rate-limiting excess. As a result, the upper limit of linearity of glucose measurement is extended to a much higher value than that which is achieved without the resistance domain. In one embodiment, the resistance domain 44 exhibits an oxygen-to-glucose permeability ratio of approximately 200:1. As a result, one-dimensional reactant diffusion is adequate to provide excess oxygen at all reasonable glucose and oxygen concentrations found in the subcutaneous matrix (See Rhodes et al., Anal. Chem., 66:1520-1529 (1994)). In some embodiments, a lower ratio of oxygen-to-glucose can be sufficient to provide excess oxygen by using a high oxygen soluble domain (for example, a silicone material) to enhance the supply/transport of oxygen to the enzyme membrane and/or electroactive surfaces. By enhancing the oxygen supply through the use of a silicone composition, for example, glucose concentration can be less of a limiting factor. In other words, if more oxygen is supplied to the enzyme and/or electroactive surfaces, then more glucose can also be supplied to the enzyme without creating an oxygen rate-limiting excess.
The resistance domain 44 is preferably formed from high oxygen soluble materials such as polymers formed from silicone, fluorocarbons, perfluorocarbons, or the like. In one embodiment, the resistance domain is formed from a silicone composition with a hydrophile such as such as polyethylene glycol, propylene glycol, pyrrolidone, esters, amides, carbonates, or polypropylene glycol covalently incorporated or grafted therein. In some alternative embodiments, the resistance domain is from polyurethane, for example, a polyurethane urea/polyurethane-block-polyethylene glycol blend.
In some embodiments, the resistance domain 44 can be formed as a unitary structure with the cell impermeable domain 42; that is, the inherent properties of the resistance domain 44 can provide the functionality described with reference to the cell impermeable domain 42 such that the cell impermeable domain 42 is incorporated as a part of resistance domain 44. In these embodiments, the combined resistance domain/cell impermeable domain can be bonded to or formed as a skin on the cell disruptive domain 40 during a molding process such as described above. In another embodiment, the resistance domain 44 is formed as a distinct layer and chemically or mechanically bonded to the cell disruptive domain 40 (if applicable) or the cell impermeable domain 42 (when the resistance domain is distinct from the cell impermeable domain).
In preferred embodiments, the thickness of the resistance domain is from about 10 microns or less to about 200 microns or more. In more preferred embodiments, the thickness of the resistance domain is from about 15, 20, 25, 30, or 35 microns to about 65, 70, 75, 80, 85, 90, 95, or 100 microns. In more preferred embodiments, the thickness of the resistance domain is from about 40 or 45 microns to about 50, 55, or 60 microns.
Enzyme Domain
An immobilized enzyme domain 46 is situated less distal from the electrochemically reactive surfaces than the resistance domain 44. In one embodiment, the immobilized enzyme domain 46 comprises glucose oxidase. In other embodiments, the immobilized enzyme domain 46 can be impregnated with other oxidases, for example, galactose oxidase, cholesterol oxidase, amino acid oxidase, alcohol oxidase, lactate oxidase, or uricase. For example, for an enzyme-based electrochemical glucose sensor to perform well, the sensor'"'"'s response should neither be limited by enzyme activity nor cofactor concentration.
The enzyme domain 44 is preferably formed from high oxygen soluble materials such as polymers formed from silicone, fluorocarbons, perfluorocarbons, or the like. In one embodiment, the enzyme domain is formed from a silicone composition with a hydrophile such as such as polyethylene glycol, propylene glycol, pyrrolidone, esters, amides, carbonates, or polypropylene glycol covalently incorporated or grafted therein.
In one preferred embodiment, high oxygen solubility within the enzyme domain can be achieved by using a polymer matrix to host the enzyme within the enzyme domain, which has a high solubility of oxygen. In one exemplary embodiment of fluorocarbon-based polymers, the solubility of oxygen within a perfluorocarbon-based polymer is 50-volume %. As a reference, the solubility of oxygen in water is approximately 2-volume %.
Utilization of a high oxygen solubility material for the enzyme domain is advantageous because the oxygen dissolves more readily within the domain and thereby acts as a high oxygen soluble domain optimizing oxygen availability to oxygen-utilizing sources (for example, the enzyme and/or counter electrode). When the resistance domain 44 and enzyme domain 46 both comprise a high oxygen soluble material, the chemical bond between the enzyme domain 46 and resistance domain 44 can be optimized, and the manufacturing made easy.
In preferred embodiments, the thickness of the enzyme domain is from about 1 micron or less to about 40, 50, 60, 70, 80, 90, or 100 microns or more. In more preferred embodiments, the thickness of the enzyme domain is between about 1, 2, 3, 4, or 5 microns and 13, 14, 15, 20, 25, or 30 microns. In even more preferred embodiments, the thickness of the enzyme domain is from about 6, 7, or 8 microns to about 9, 10, 11, or 12 microns.
Interference Domain
The interference domain 48 is situated less distal to the implantable device than the immobilized enzyme domain. Interferants are molecules or other species that are electro-reduced or electro-oxidized at the electrochemically reactive surfaces, either directly or via an electron transfer agent, to produce a false signal (for example, urate, ascorbate, or acetaminophen). In one embodiment, the interference domain 48 prevents the penetration of one or more interferants into the electrolyte phase around the electrochemically reactive surfaces. Preferably, this type of interference domain is much less permeable to one or more of the interferants than to the analyte.
In one embodiment, the interference domain 48 can include ionic components incorporated into a polymeric matrix to reduce the permeability of the interference domain to ionic interferants having the same charge as the ionic components. In another embodiment, the interference domain 48 includes a catalyst (for example, peroxidase) for catalyzing a reaction that removes interferants. U.S. Pat. Nos. 6,413,396 and 6,565,509 disclose methods and materials for eliminating interfering species; however in the preferred embodiments any suitable method or material can be employed.
In another embodiment, the interference domain 48 includes a thin membrane that is designed to limit diffusion of species, for example, those greater than 34 kD in molecular weight, for example. The interference domain permits analytes and other substances (for example, hydrogen peroxide) that are to be measured by the electrodes to pass through, while preventing passage of other substances, such as potentially interfering substances. In one embodiment, the interference domain 48 is constructed of polyurethane. In an alternative embodiment, the interference domain 48 comprises a high oxygen soluble polymer, such as described above.
In preferred embodiments, the thickness of the interference domain is from about 0.1 microns or less to about 10 microns or more. In more preferred embodiments, the thickness of the interference domain is between about 0.2, 0.3, 0.4, or 0.5 microns and about 5, 6, 7, 8, or 9 microns. In more preferred embodiments, the thickness of the interference domain is from about 0.6, 0.7, 0.8, 0.9, or 1 micron to about 2, 3, or 4 microns.
Electrolyte Domain
An electrolyte domain 50 is situated more proximal to the electrochemically reactive surfaces than the interference domain 48. To ensure the electrochemical reaction, the electrolyte domain 30 includes a semipermeable coating that maintains hydrophilicity at the electrochemically reactive surfaces of the sensor interface. The electrolyte domain 50 enhances the stability of the interference domain 48 by protecting and supporting the material that makes up the interference domain. The electrolyte domain also 50 assists in stabilizing the operation of the device by overcoming electrode start-up problems and drifting problems caused by inadequate electrolyte. The buffered electrolyte solution contained in the electrolyte domain also protects against pH-mediated damage that can result from the formation of a large pH gradient between the substantially hydrophobic interference domain and the electrodes due to the electrochemical activity of the electrodes. In some embodiments, the electrolyte domain may not be used, for example, when an interference domain is not provided.
In one embodiment, the electrolyte domain 50 includes a flexible, water-swellable, substantially solid gel-like film having a “dry film” thickness of from about 2.5 microns to about 12.5 microns, more preferably from about 3, 3.5, 4, 4.5, 5, or 5.5 to about 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, or 12 microns. “Dry film” thickness refers to the thickness of a cured film cast from a coating formulation onto the surface of the membrane by standard coating techniques.
In some embodiments, the electrolyte domain 50 is formed of a curable mixture of a urethane polymer and a hydrophilic polymer. Particularly preferred coatings are formed of a polyurethane polymer having anionic carboxylate functional groups and non-ionic hydrophilic polyether segments, which is crosslinked in the presence of polyvinylpyrrolidone and cured at a moderate temperature of about 50° C. In some preferred embodiments, the electrolyte domain 50 is formed from high oxygen soluble materials such as polymers formed from silicone, fluorocarbons, perfluorocarbons, or the like.
In one preferred embodiment, the electrolyte domain 50 is formed from a high oxygen soluble material, such as described above. In preferred embodiments, the thickness of the electrolyte domain is from about 1 micron or less to about 40, 50, 60, 70, 80, 90, or 100 microns or more. In more preferred embodiments, the thickness of the electrolyte domain is from about 2, 3, 4, or 5 microns to about 15, 20, 25, or 30 microns. In even more preferred embodiments, the thickness of the electrolyte domain is from about 6, 7, or 8 microns to about 9, 10, 11, or 12 microns.
Underlying the electrolyte domain is an electrolyte phase is a free-fluid phase including a solution containing at least one compound, typically a soluble chloride salt, which conducts electric current. In one embodiment wherein the membrane system is used with a glucose sensor such as is described herein, the electrolyte phase flows over the electrodes and is in contact with the electrolyte domain. The devices of the preferred embodiments contemplate the use of any suitable electrolyte solution, including standard, commercially available solutions. Generally, the electrolyte phase can have the same osmotic pressure or a lower osmotic pressure than the sample being analyzed. In preferred embodiments, the electrolyte phase comprises normal saline.
In various embodiments, any of these domains can be omitted, altered, substituted for, and/or incorporated together without departing from the spirit of the preferred embodiments. For example, a distinct cell impermeable domain may not exist. In such embodiments, other domains accomplish the function of the cell impermeable domain. As another example, the interference domain can be eliminated in certain embodiments wherein two-electrode differential measurements are employed to eliminate interference, for example, one electrode being sensitive to glucose and electrooxidizable interferants and the other only to interferants, such as is described in U.S. Pat. No. 6,514,718. In such embodiments, the interference domain can be omitted.
A variety of configurations are contemplated with the membrane systems of the preferred embodiments, however the exemplary configurations are not meant to be limiting and may be modified within the scope of the preferred embodiments. In one embodiment, the enzyme domain is formed from a material with a high oxygen solubility, which is believed to optimize oxygen availability to the enzyme immobilized therein. In another embodiment, all domains between the fluid supply (for example, interstitial fluid) and the enzyme (up to and including the enzyme domain) are formed from a material with a high oxygen solubility, which is believed to dynamically retain a substantially continuous path of high oxygen availability to the enzyme and/or electroactive surfaces during local ischemic periods. In yet another embodiment, all domains of a membrane system are formed from high oxygen soluble materials; in this way, the membrane system transports and/or maintains high oxygen availability substantially continuously across the membrane system, from the interstitial fluid to the implantable device surface, providing increased oxygen availability to the implantable device, for example electroactive surfaces thereon or transplanted cells located therein. While not wishing to be bound by theory, it is believed that maintaining high oxygen availability at the interface of the implantable device improves device performance even during transient ischemia and other low oxygen situations.
Reference is now made to
The upper dashed lines represent oxygen concentration in the fluid source (Cf) and oxygen concentration in the membrane system (Cm) at equilibrium (namely, without oxygen utilization) under normal conditions. However, when the membrane system 54a interfaces with an oxygen-utilizing source 56, oxygen concentration within the membrane system will be utilized. Accordingly, line 58a represents oxygen concentration under normal conditions decreasing at steady state as it passes through the membrane system 54a to the oxygen-utilizing source 56. While not wishing to be bound by theory, the oxygen concentration at the interface between the membrane system 54a and the oxygen-utilizing source 56 provides sufficient oxygen under normal conditions for oxygen-utilizing sources in vivo, such as enzymatic reactions, cellular processes, and electroactive surfaces.
Unfortunately, “normal conditions” do not always occur in vivo, for example during transient ischemic periods, such as described in more detail above with reference to
Referring to
The upper dashed lines represent oxygen concentration in the fluid source (Cf) and oxygen concentration in the membrane system (Cm) at equilibrium (namely, without oxygen utilization) under normal conditions. The membrane system of the preferred embodiments 54b is illustrated with a significantly higher oxygen concentration than the conventional membrane 54a. This higher oxygen concentration at equilibrium is attributed to higher oxygen solubility inherent in the properties of the membrane systems of the preferred embodiments as compared to conventional membrane materials. Line 58b represents oxygen concentration under normal conditions decreasing at steady state as it passes through the membrane system 54b to the oxygen-utilizing source 56. While not wishing to be bound by theory, the oxygen concentration at the interface between the membrane system 54b and the oxygen-utilizing source 56 is believe to provide sufficient oxygen under normal conditions for oxygen-utilizing sources in vivo, such as enzymatic reactions, cellular processes, and electroactive surfaces.
Such as described above, “normal conditions” do not always occur in vivo, for example during transient ischemic periods, wherein oxygen concentration is decreased below normal to a concentration as low as zero. Accordingly, line 60b represents oxygen concentration during ischemic conditions, wherein the oxygen concentration of the fluid source (Cf) is approximately half of its normal concentration. Because of the linear relationship between the fluid source oxygen concentration (Cf) and the membrane system oxygen concentration (Cm), the membrane system oxygen concentration, which is represented by a line 62b, is approximately half of its normal concentration. In contrast to the conventional membrane 62a illustrated in
Methods and devices that are suitable for use in conjunction with aspects of the preferred embodiments are disclosed in co-pending U.S. patent application Ser. No. 10/842,716, filed May 10, 2004 and published as U.S. Application Publication No. 2005-0031689 and entitled, “MEMBRANE SYSTEMS INCORPORATING BIOACTIVE AGENTS”; co-pending U.S. patent application Ser. No. 10/838,912 filed May 3, 2004 and published as U.S. Application Publication No. 2005-0245799 and entitled, “IMPLANTABLE ANALYTE SENSOR”; U.S. patent application Ser. No. 10/789,359 filed Feb. 26, 2004 and published as U.S. Application Publication No. 2005-0192557 and entitled, “INTEGRATED DELIVERY DEVICE FOR A CONTINUOUS GLUCOSE SENSOR”; U.S. application Ser. No. 10/695,636 filed Oct. 28, 2003 and published as U.S. Application Publication No. 2005-0090607 and entitled, “SILICONE COMPOSITION FOR BIOCOMPATIBLE MEMBRANE”; U.S. application Ser. No. 10/648,849 and published as U.S. Application Publication No. 2005-0043598 filed Aug. 22, 2003 and entitled, “SYSTEMS AND METHODS FOR REPLACING SIGNAL ARTIFACTS IN A GLUCOSE SENSOR DATA STREAM”; U.S. application Ser. No. 10/646,333 filed Aug. 22, 2003 and published as U.S. Application Publication No. 2004-0199059 and entitled, “OPTIMIZED SENSOR GEOMETRY FOR AN IMPLANTABLE GLUCOSE SENSOR”; U.S. application Ser. No. 10/647,065 filed Aug. 22, 2003 and published as U.S. Application Publication No. 2005-0112169 entitled, “POROUS MEMBRANES FOR USE WITH IMPLANTABLE DEVICES”; U.S. application Ser. No. 10/633,367 filed Aug. 1, 2003 and published as U.S. Application Publication No. 2005-0027463 and entitled, “SYSTEM AND METHODS FOR PROCESSING ANALYTE SENSOR DATA”; U.S. Pat. No. 6,702,857 entitled “MEMBRANE FOR USE WITH IMPLANTABLE DEVICES”; U.S. application Ser. No. 09/916,711 filed Jul. 27, 2001 and published as U.S. Application Publication No. 2003-0032874 and entitled “SENSOR HEAD FOR USE WITH IMPLANTABLE DEVICE”; U.S. application Ser. No. 09/447,227 filed Nov. 22, 1999 and entitled “DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS”; U.S. application Ser. No. 10/153,356 filed May 22, 2002 and published as U.S. Application Publication No. 2003-0217966 and entitled “TECHNIQUES TO IMPROVE POLYURETHANE MEMBRANES FOR IMPLANTABLE GLUCOSE SENSORS”; U.S. application Ser. No. 09/489,588 filed Jan. 21, 2000 and issued as U.S. Pat. No. 6,741,877 and entitled “DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS”; U.S. application Ser. No. 09/636,369 filed Aug. 11, 2000 and issued as U.S. Pat. No. 6,558,321 and entitled “SYSTEMS AND METHODS FOR REMOTE MONITORING AND MODULATION OF MEDICAL DEVICES”; and U.S. application Ser. No. 09/916,858 filed Jul. 27, 2001 and issued as U.S. Pat. No. 6,862,465 and entitled “DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS,” as well as issued patents including U.S. Pat. No. 6,001,067 issued Dec. 14, 1999 and entitled “DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS”; U.S. Pat. No. 4,994,167 issued Feb. 19, 1991 and entitled “BIOLOGICAL FLUID MEASURING DEVICE”; and U.S. Pat. No. 4,757,022 filed Jul. 12, 1988 and entitled “BIOLOGICAL FLUID MEASURING DEVICE”; U.S. Appl. No. 60/489,615 filed Jul. 23, 2003 and entitled “ROLLED ELECTRODE ARRAY AND ITS METHOD FOR MANUFACTURE”; U.S. Appl. No. 60/490,010 filed Jul. 25, 2003 and entitled “INCREASING BIAS FOR OXYGEN PRODUCTION IN AN ELECTRODE ASSEMBLY”; U.S. Appl. No. 60/490,208 filed Jul. 25, 2003 and entitled “ELECTRODE ASSEMBLY WITH INCREASED OXYGEN GENERATION”; U.S. Appl. No. 60/490,007 filed Jul. 25, 2003 and entitled “OXYGEN-GENERATING ELECTRODE FOR USE IN ELECTROCHEMICAL SENSORS”; U.S. application Ser. No. 10/896,637 filed on Jul. 21, 2004 and published as U.S. Application Publication No. 2005-0051427 and entitled “ROLLED ELECTRODE ARRAY AND ITS METHOD FOR MANUFACTURE”; U.S. application Ser. No. 10/896,772 filed on Jul. 21, 2004 and published as U.S. Application Publication No. 2005-0056552 and entitled “INCREASING BIAS FOR OXYGEN PRODUCTION IN AN ELECTRODE ASSEMBLY”; U.S. application Ser. No. 10/897,377 filed on Jul. 21, 2004 and published as U.S. Application Publication No. 2005-0051440 and entitled “ELECTROCHEMICAL SENSORS INCLUDING ELECTRODE SYSTEMS WITH INCREASED OXYGEN GENERATION”; U.S. application Ser. No. 10/89,7312 filed on Jul. 21, 2004 and published as U.S. Application Publication No. 2005-0115832 and entitled “ELECTRODE SYSTEMS FOR ELECTROCHEMICAL SENSORS”. The foregoing patent applications and patents are incorporated herein by reference in their entireties.
All references cited herein are incorporated herein by reference in their entireties. To the extent publications and patents or patent applications incorporated by reference contradict the disclosure contained in the specification, the specification is intended to supersede and/or take precedence over any such contradictory material.
The term “comprising” as used herein is synonymous with “including,” “containing,” or “characterized by,” and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps.
All numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that can vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should be construed in light of the number of significant digits and ordinary rounding approaches.
The above description discloses several methods and materials of the present invention. This invention is susceptible to modifications in the methods and materials, as well as alterations in the fabrication methods and equipment. Such modifications will become apparent to those skilled in the art from a consideration of this disclosure or practice of the invention disclosed herein. Consequently, it is not intended that this invention be limited to the specific embodiments disclosed herein, but that it cover all modifications and alternatives coming within the true scope and spirit of the invention as embodied in the attached claims.